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Purpose: Patient-specific IMRT QA measurements are important components of processes designed
to identify discrepancies between calculated and delivered radiation doses. Discrepancy tolerance
limits are neither well defined nor consistently applied across centers. The AAPM TG-218 report
provides a comprehensive review aimed at improving the understanding and consistency of these
processes as well as recommendations for methodologies and tolerance limits in patient-specific
IMRT QA.
Methods: The performance of the dose difference/distance-to-agreement (DTA) and c dose distribu-
tion comparison metrics are investigated. Measurement methods are reviewed and followed by a dis-
cussion of the pros and cons of each. Methodologies for absolute dose verification are discussed and
new IMRT QA verification tools are presented. Literature on the expected or achievable agreement
between measurements and calculations for different types of planning and delivery systems are
reviewed and analyzed. Tests of vendor implementations of the c verification algorithm employing
benchmark cases are presented.
Results: Operational shortcomings that can reduce the c tool accuracy and subsequent effec-
tiveness for IMRT QA are described. Practical considerations including spatial resolution, nor-
malization, dose threshold, and data interpretation are discussed. Published data on IMRT QA
and the clinical experience of the group members are used to develop guidelines and recom-
mendations on tolerance and action limits for IMRT QA. Steps to check failed IMRT QA
plans are outlined.
Conclusion: Recommendations on delivery methods, data interpretation, dose normalization, the
use of c analysis routines and choice of tolerance limits for IMRT QA are made with focus on detect-
ing differences between calculated and measured doses via the use of robust analysis methods and an
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in-depth understanding of IMRT verification metrics. The recommendations are intended to improve
the IMRT QA process and establish consistent, and comparable IMRT QA criteria among institu-
tions. © 2018 American Association of Physicists in Medicine [https://doi.org/10.1002/mp.12810]
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1.A. Background and importance
The idea of conformal radiotherapy using intensity modula-
tion was presented in the early 1990s1–3 with delivery systems
first contemplated and shortly thereafter developed.4,5 By the
mid 1990s, reports of the first clinical experience with intensity
modulated radiation therapy (IMRT) were published6,7 with the
commissioning and quality assurance (QA) of such systems
published simultaneously.8,9 IMRT delivery techniques can be
divided into two broad categories, fixed and moving gantry.
Fixed-gantry IMRT delivery employs step-and-shoot (or seg-
mental), sliding window (dynamic), or compensator-based
methods. Moving gantry IMRT delivery includes spiral or
sequential tomotherapy4,10 and volumetric modulated arc ther-
apy (VMAT). The tomotherapy technique uses specialized bin-
ary multileaf collimators (MLCs), with only open and closed
positions. VMAT requires dynamic MLC delivery along with
continuously variable or quantized dose rate and gantry
motion.11–13 IMRT dose distributions are typically much more
heterogeneous than those of three-dimensional (3D) plans,
employing complex fields that incorporate different degrees of
modulation. Since the inception of IMRT, procedures for the
delivery system and patient-specific IMRT plan QA have
emerged10 based on measurement and calculation techniques
including independent monitor unit (MU) calculations for
IMRT.14 IMRT QA verification is an important process
employed to check the accuracy of IMRT plan dose calculations
and to detect clinically relevant errors in the radiation delivery,
thereby ensuring the safety of patients and fidelity of treatment.
Several components must be addressed when clinically
implementing IMRT such as acceptance and commissioning
of the delivery device and treatment planning system (TPS),
and development and implementation of a comprehensive
IMRT QA program. An early American Association of
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Physicists in Medicine (AAPM) report on IMRT clinical
implementation described delivery systems and pretreatment
QA.15 In 2009, additional details concerning IMRT commis-
sioning were addressed including tests and sample accuracy
results for different IMRT planning and delivery systems.16 In
2011, strengths and weaknesses of different dosimetric tech-
niques and the acquisition of accurate data for commissioning
patient-specific measurements were addressed.17 A compre-
hensive White Paper on safety considerations in IMRT was
also published, which clearly specified that pretreatment vali-
dations were necessary18 for patient safety, but the goal of the
White Paper was not to explicitly address how that validation
should be done. Other possibilities besides measurements
have been published including, independent computer calcu-
lations, check-sum approaches, and log file analysis.14,19–24
Several professional organizations [AAPM, American Col-
lege of Radiology (ACR), American Society for Radiation
Oncology (ASTRO)]15,16,18,25 have strongly recommended
patient-specific IMRT QA be employed as part of the clinical
IMRT process. A series of New York Times articles high-
lighted to the general public the hazard to patients when
patient-specific IMRT QA was not performed after a change
to a patient’s treatment plan was made.26,27
While the value of patient-specific IMRT QA has been
debated among physicists,19,28–30 especially whether compu-
tational methods can replace physical measurements, mea-
surement-based patient-specific IMRT QA methods are
widely used and are the core element of most IMRT QA pro-
grams. In many centers, a QA measurement is routinely per-
formed after a patient’s IMRT plan is created and approved
by the radiation oncologist. The treatment plan consisting of
MLC leaf sequence files (or compensators) as a function of
gantry angle and MUs from the patient’s plan is computed
on a homogeneous phantom to calculate dose in the QA
measurement geometry. The physical phantom is irradiated
under the same conditions to measure the dose. The calcula-
tions and measurements are compared and approved or
rejected using the institution’s criteria for agreement. If the
agreement is deemed acceptable, then one infers that the
delivered patient plan will be accurate within clinically
acceptable tolerances. This phantom plan does not check the
algorithm’s management of heterogeneities, segmentation
errors, or patient positioning errors. The details of methods
used to evaluate the agreement between measured and calcu-
lated dose distributions (e.g., how a c evaluation has been
implemented), however, are often poorly understood by the
medical physicists. For example, if the tolerance limits have
not been thoroughly evaluated, it will be difficult to assess
with any degree of confidence that these limits were clini-
cally appropriate. To this end, the AAPM Therapy Physics
Committee (TPC) formed Task Group (TG)-218 with the
following charges:
 To review literature and reports containing data on the
achieved agreement between measurements and calcu-
lations for fixed-gantry IMRT, VMAT, and tomotherapy
techniques.
 To review commonly used measurement methods: com-
posite of all beams using the actual treatment parameters,
perpendicular composite, and perpendicular field-by-
field. Discuss pros and cons of each method.
 To review single-point (small-averaged volume), 1D
and 2D analysis methodologies for absolute dose verifi-
cation with ion chamber and 2D detector arrays, mainly
performed with dose differences comparison, distance-
to-agreement (DTA) comparison between measured
and calculated dose distributions, and a combination of
these two metrics (c method).
 To investigate the dose difference/DTA and c verifica-
tion metrics, their use and vendor-implementation vari-
ability, including the choice of various parameters used
to perform the IMRT QA analysis.
The objective of this report is to address these charges.
The report provides recommendations on tolerance limits and
measurement methods. Specifically, various measurement
methods are reviewed and discussed. The dose difference/
DTA and c verification metrics are examined in-depth. Data
on the expected or achievable agreement between measure-
ments and calculations for different types of planning and
delivery systems are reviewed. Results from a test suite devel-
oped by TG-218 to evaluate vendors’ dose comparison soft-
ware under well-regulated conditions are presented.
Recommendations on the use of c analysis routines and
choice of tolerance limits are made.
1.B. Uncertainties in the IMRT planning and
delivery process
Acceptance criteria for initial machine and TPS commis-
sioning are well established.31,32 The acceptance criteria for
patient-specific IMRT QA, however, are more difficult to
establish because of large variations among IMRT planning
systems, delivery systems, and measurement tools.33–36 There
are many sources of errors in IMRT planning and delivery. In
terms of treatment planning, the error sources can include
modeling of the: MLC leaf ends, MLC tongue-and-groove
effects, leaf/collimator transmission, collimators/MLC
penumbra, compensator systems (scattering, beam hardening,
alignment), output factors for small field sizes, head
backscatter, and off-axis profiles. They can also include a
selection of the dose calculation grid size and the use and
modeling of heterogeneity corrections. Accurate IMRT TPS
beam modeling is essential to reduce the uncertainties associ-
ated with the TPS planning process and consequently ensure
good agreement between calculations and measurements
when performing patient-specific verification QA.37,38
Spatial and dosimetric delivery system uncertainties also
affect IMRT dose distribution delivery accuracy. These
uncertainties include: MLC leaf position errors (random and
systematic), MLC leaf speed acceleration/deceleration, gantry
rotational stability, table motion stability, and beam stability
(flatness, symmetry, output, dose rate, segments with low
MUs). In addition, differences and limitations in the design
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of the MLC and accelerators, including the treatment head
design, as well as the age of the accelerator/equipment can
have an impact on the accuracy of IMRT delivery tech-
niques.37,38
Another source of uncertainty among clinics using mea-
surement-based patient-specific IMRT QA programs is the
measurement and analysis tools used to interpret the QA
results.39–43 These software tools have several parameters that
must be chosen to perform the analysis and the results can
vary significantly depending on those choices. One example is
the selection of whether to use global or local dose normaliza-
tion to compare measured and calculated dose distributions.
1.C. Tolerances and action limits
Quality measures are employed to validate system perfor-
mance,44,45 such as IMRT QA. In this report, action limits
are defined as the amount the quality measures are allowed
to deviate without risking harm to the patient35 as well as
defining limit values for when clinical action is required. An
example for IMRT QA is the decision not to treat the patient
if the comparison between a point-dose measurement and
the planned value exceeds a predefined acceptance criterion
(e.g., 5%). These limits will depend on whether one is
using relative or absolute dose differences and/or explicitly
excluding low-dose regions from the analysis. Action limits
should be set based on clinical judgment regarding the
acceptability of a specific quality measure deviation.
Tolerance limits are defined as the boundaries within
which a process is considered to be operating normally,
that is, subject to only random errors. Results outside of
the tolerance limits (or trends moving rapidly toward these
boundaries) provide an indication that a system is deviat-
ing from normal operation. The measurement results that
lie outside the tolerance limits should be investigated to
determine if their cause could be identified and fixed. The
intent of this approach is to fix issues before they reach
clinically unacceptable thresholds or action limits. When
using action and tolerance limits, it is assumed that a care-
ful commissioning process was followed. During the com-
missioning process, systematic errors should be identified
and eliminated to the degree possible. This approach can
also inform the choice of action limits when ambiguity
exists about the clinical impact of exceeding action limits.
This report will provide recommendations on one process-
based method to choose these limits and accounts for both
random errors and any residual systematic errors from the
commissioning process.
2. DOSE DIFFERENCE, DTA, c ANALYSIS, AND
VERIFICATION METRICS
Dose distributions are almost always represented as arrays
of points, each defined by a location and dose value. The
spacing between the points is the spatial resolution of the dis-
tribution and does not need to be the same in all spatial
dimensions or locations. The spatial resolution of the dose
distribution plays an important role in its display and evalua-
tion. Coarse dose distributions may require some type of
interpolation to display in an easily interpretable form, such
as isodose lines or dose color washes. Dose distribution reso-
lution also plays a role in dose distribution comparisons.
Some comparison techniques are degraded by coarse resolu-
tion, so interpolation is employed.
This discussion of dose comparison techniques will
assume that there are two distributions, termed a “reference”
and an “evaluated” dose. The reference distribution is typi-
cally the one against which the evaluated distribution is being
compared; although the specific mathematics and limitations
of the comparison techniques may require these roles to be
reversed. Some of the comparison techniques are invariant
with respect to selection of the reference and evaluated distri-
bution and some are not.
The process of dose comparison is part of a clinical work-
flow, in which the goal is to determine if the reference and
evaluated dose distributions agree to within limits that are
clinically relevant. The question of clinical relevance involves
more than the dose itself, it also involves the dose gradients
as well as dose errors resulting from spatial uncertainties.
There is therefore a need to understand both the spatial and
dosimetric uncertainties when conducting dose distribution
comparisons. The spatial analog to the dose difference is the
DTA, which in general refers to the distance between com-
mon features of the two dose distributions.
The positional accuracy specification of a steep dose gra-
dient region should at least in part be based on the accuracy
of patient positioning. Setting IMRT QA tolerances tighter
than the ultimate clinical requirement will lead to unneces-
sary effort in attempting to reduce respective errors. Finally,
in some cases, the spatial uncertainty can be related simply to
experimental error. Even if the user insists on having zero
spatial error in a calculation, or if the calculation is being
used for an extremely accurate dose delivery process, the
dose distribution measurements have some spatial uncer-
tainty. Therefore, the DTA criterion can also be partly defined
based on the measurement error.
2.A. Challenges for comparing dose distributions
On the surface, comparing dose distributions would appear
to be straightforward. The distributions are no more than
arrays of numbers, and a straightforward method for compar-
ing is to calculate their numerical difference. However, in
steep dose gradient regions, the dose difference is extremely
sensitive to spatial misalignments. This sensitivity leads to
large dose differences that easily exceed the dose difference
criteria even for clinical irrelevant spatial misalignments.
A common method for comparing dose distributions is to
overlay their contours. This technique provides a rapid and
qualitative method for comparing the distributions. If the dis-
tributions agree exactly, the contours will overlay and if not,
they will separate. The separation distance will depend on
two factors; the difference in the doses and the local dose gra-
dients. When the gradients are steep, contours move only
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slightly with changes in dose, so even large dose errors will
correspond to small contour separations. Therefore, compar-
ing contours in steep dose gradient regions provides little
insight as to the dose differences because it takes very large
differences to significantly move the lines. On the other hand,
even small dose differences will move isodose lines far in
low-dose gradient regions. The only places where contour
plots easily provide quantitative information are where iso-
dose lines cross or superimpose. If the isodose lines are the
same values, the distributions agree exactly at those locations.
If two different isodose lines cross, for example the 50% line
from one distribution and the 60% line from the other distri-
bution, the dose difference is known at the crossing point.
Otherwise, superimposed isodose contours provide little
quantitative information.
Figure 1 shows an example of superimposed isodoses
from Brulla–Gonzalez.46 The isodoses represent measured
dose distributions from radiochromic film and a 2D
dosimeter. The correspondence between the two dose dis-
tributions is clear, and shows that there is no extensive
disagreement, although disagreements of a few percent are
difficult to determine. Figure 2 shows two dose distribu-
tions that greatly disagree.47 The fact that they disagree is
instantly clear from the vastly different isodose lines. In
this case, additional quantitative dose analysis may be
unnecessary.
One of the more challenging aspects of phantom-based
dose distribution comparisons is the difference between the
phantom and patient doses due to their differing geome-
tries.48 For measurements intended to evaluate planned
dose accuracy, the comparison criteria would ideally be
based on clinical organ-by-organ tolerances. For example,
the tumor dose tolerance specification might be 3%, while
a looser criterion of 10% might be acceptable to some
muscle receiving 10 Gy and similarly with spatial toler-
ances. The spatial accuracy requirement might be 2 mm at
the edge of the spinal cord, but 5 mm or more in the
muscle. Because the measurements are conducted in phan-
toms, the planned fluence distribution does not lead to the
clinical dose distribution, even if there are no planning or
delivery errors, simply because the dose deposited in the
phantom has a different pattern than the dose deposited in
the patient. Even if the spatial locations of the organs and
tumor are superimposed on the phantom, the dose distri-
butions will typically not conform to them because of the
differences in the attenuation and scatter properties
between the phantom and patient. Therefore, for evalua-
tions such as patient-specific QA in phantom, we have
conventionally relied on more generic acceptance criteria,
based on overall goals of dosimetric and spatial accuracy
in the domain in which we are able to measure.
2.B. Dose difference test
The dose difference test is the most straightforward test to
understand and interpret. The dose difference at location r~ð Þ
is the numerical difference d between the evaluated dose
De r~ð Þ and the reference dose Dr r~ð Þ at that location. Mathe-
matically, the dose difference can be written as
d r~ð Þ ¼ De r~ð Þ  Dr r~ð Þ
Note that the doses are sampled at the same positions.
This analysis is straightforward when the dose distribution
elements occupy the same locations (i.e., same grid resolu-
tion), but spatial interpolation is required when they do not.
The dose difference test is invariant to within a sign with
respect to the selection of the reference and evaluated distri-
butions; all that happens if they are swapped is that the sign
of the dose difference changes.
The dose difference test is excellent at providing the user
insight as to the concordance between the two distributions in
low-dose gradient regions. In these regions, the dose changes
slowly with location, and the dose difference is indicative of
FIG. 2. Superimposed isodose distribution for two different dose distribu-
tions. The fact that the distributions disagree is clear from the intersecting
isodose lines, but a quantitative evaluation of the discrepancy by eye is


























FIG. 1. Isodose overlay of two measurements, the solid line from radiochro-
mic film and the dashed line from liquid-filled ionization chambers. From
Brulla–Gonzalez.46 The 20%, 50%, 70%, 80%, 90%, and 95% dose levels
are shown.
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the disagreement between the two distributions independent
of spatial uncertainties. Therefore, the spatial error toler-
ances, or DTA criteria, can be ignored. The opposite is true
in regions of steep dose gradient. Even large dose errors will
result in effectively moving the dose only a short distance in
a steep dose gradient region. Therefore, if there is a nonzero
DTA tolerance, it may not be violated even for a large dose
difference.
Because small spatial shifts can lead to large dose differ-
ences, regions may fail a dose difference test but still be clini-
cally acceptable because the shift is small. Since the clinical
reality is that the spatial relationship between the planned and
delivered dose almost always matters, the dose difference dis-
tribution alone is insufficient to determine if the dose distri-
butions agree to within the clinical tolerances. Figure 3(a)
shows an example of two dose distributions, a film-measured
and calculated plane from an IMRT treatment plan, shown in
gray-scale.49 The dose difference is shown in Fig. 3(b) and
highlights two regions of discrepancy. The regions to the left
and right correspond to opposite signs of the dose discrep-
ancy and have differences of up to 15%, all within the steep
dose gradient regions. Dose differences such as these are very
large considering the 3% dose difference criterion selected by
the investigators.
2.C. DTA test
Van Dyk et al.32 used the concept of distance-to-agree-
ment (DTA) in 1993 for treatment planning QA. They speci-
fied that the distance between two dose distributions rather
than the dose difference should be the acceptance criterion in
steep dose gradient regions.
Harms et al.50 codified the Van Dyk et al.32 distance
criteria into an algorithm. They defined the DTA for a
point in the reference distribution as the closest location in
the evaluated dose distribution with the same dose as the
point in the reference distribution. Unlike the dose differ-
ence test, this algorithm required a search of the evaluated
dose distribution to identify the closest distance to the
point in the reference distribution that had the same dose
as that point, equivalent to finding the closest distance of
the evaluated distribution isodose line.
The DTA evaluation is ideal for determining the separation
between steep dose gradient regions. However, as a compar-
ison between dose distributions, it becomes oversensitive in
low-dose gradient regions, where even a small dose differ-
ence causes the relevant isodose line to move far from the ref-
erence point. Because of this, and because most dose
distributions are dominated by low-dose gradient regions,
FIG. 3. (a) Film and calculated dose distributions from Bogner et al.49 (b) Dose difference distribution (percent of prescription dose) showing that large dose dif-
ferences can occur in steep dose gradient regions, even for dose distributions that are otherwise similar. (c) c distribution based on 3% dose difference and 3 mm
DTA.
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DTA distributions are difficult to interpret and by themselves
not very useful.
Because the DTA test involves a search, the DTA value
is not invariant to the selection of which distribution is
selected as the reference. The reference distribution can
have any resolution and dimensionality because the DTA
is calculated point by point in the reference distribution,
but the evaluated distribution usually has at least the same
or greater resolution and dimensionality than the reference
distribution.
2.D. Composite test
Given that the dose difference and DTA tests were com-
plementary in their sensitivity to low and steep dose gradient
regions, respectively, it made sense to combine the two, so
one could determine if a reference point had passed both the
dose difference and DTA tests. Harms et al.50 termed this the
composite test. A reference point was said to have passed if it
passed either the dose difference or DTA tests. Only if it
failed both tests was it determined that it had failed the com-
parison. While the composite test automatically managed
both steep and low-dose gradient regions, it suffered from
being strictly a pass-fail test. If a point failed, the test did not
indicate by how much.
2.E. c test
The lack of insight as to the magnitude of failure with the
composite test led Low et al.43,51 to generalize the test. They
treated the dose distribution comparison from a geometric
perspective by evaluating the displacement between the refer-
ence and evaluated distributions. This evaluation was con-
ducted independently for each reference dose point. Similar
to the DTA test, the dimensionality of the reference distribu-
tion could be a single point, while the evaluated distribution
needed to be at least one dimensional.
The question of the displacement between dose distribu-
tions was complicated by the fact that there were n+1 degrees
of freedom, where n referred to the spatial dimensionality of
the comparison (e.g., a film plane contains two spatial and
one dose dimension). The dose distribution could be thought
of as an n-dimensional sheet within the n+1 dimensional
space. The problem with determining a displacement in that
space was that one of the axes was dose, while the others
were distance. A displacement measurement was meaningless
in this multiple-quantity space.
In order to allow the measurement to be defined, the dose
and displacement scales were renormalized to be unitless by
dividing them by the dose (DD) and DTA (Dd) criteria,
respectively.
The displacement between two points, r~r and r~e in the ref-
erence and evaluated distributions, respectively, in the renor-
malized space was termed c,









where r r~e;rrð Þ was the distance between the reference and
evaluated points, and d r~e;rrð Þ was the dose difference. The
minimum displacement was defined as c
c r~rð Þ ¼ min C r~e; r~rð Þf g8 r~ef g (2)
Values of c between 0 and 1 indicated that the comparison
passed with respect to the dose and distance criteria. Values
greater than 1 indicated failure. Because c was the displace-
ment between the two distributions, c was essentially the
radius between the reference point and the evaluated distribu-
tion, so the pass/fail criteria were essentially the circle,
sphere, or hypersphere in 1, 2, and 3 dimensional dose distri-
bution comparisons, respectively. This was similar to the
composite test, and in fact comparisons between the two tests
showed little in the way of differences between points that
passed and failed, although the c test was shown to be
slightly more forgiving than the composite test for clinical
dose distributions.43
While the c test provided more than a pass/fail compar-
ison, this did not itself allow a straightforward interpretation
of the test’s meaning. The most effective method of gaining














FIG. 4. Examples of one-dimensional c dose comparison analyses in low (a) and steep (b) dose gradients. The closest approach that the evaluated distribution
makes to the reference point is c. For low-dose gradients, the c test is essentially the dose difference test. For steep dose gradients, the c test is essentially the
DTA test.
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examine how the test behaved in two extreme conditions, one
of near zero dose gradient and one of steep dose gradients.
Figure 4 shows examples of 1D dose distributions with
low and steep dose gradients. The c calculation found the
closest approach of the evaluated dose distribution to the ref-
erence dose distribution. With low-dose gradients, the vector
connecting the reference point to the evaluated distribution
lies nearly parallel to the dose axis [Fig. 4(a)]. The dose dif-
ference test could be interpreted as the distance between the
two distributions along the dose axis, which is what the c test
defaulted to in the conditions of a zero dose gradient. There-
fore, the c test defaulted to the dose difference test (within
the normalization of the dose difference criterion) in low-
dose gradient regions, precisely where the dose difference
test was most useful.
Figure 4(b) shows the c test under conditions of steep
dose gradients. In this case, the c vector lies nearly parallel to
the distance axis, or distance axes for 2D and 3D dose distri-
butions. The DTA test could be interpreted as the closest
point where the evaluated dose distribution crossed the dis-
tance axes (with the origin placed at the reference point).
Therefore, as the gradient increased, the c test became the
DTA test as normalized by the DTA criterion.
The main benefit of the c comparison tool was that it auto-
matically reduced the sensitivity of dose distribution compar-
isons in steep dose gradient regions. Figure 3(c) shows an
example of c for the dose distribution comparisons shown in
Fig. 3(b).
2.F. Other tools
A number of IMRT QA evaluation tools have been devel-
oped and reported in the literature.52–54 The gradient com-
pensation method was developed by Moran et al.52 They
computed the local dose gradient for each point in the dose
distribution. A user-selected distance parameter was chosen
to allow for geometric uncertainties due, for example to
experimental error or calculation grid resolution. The dose
gradient at each point was multiplied by this distance parame-
ter to yield a dose value corresponding to the resulting uncer-
tainty in dose due to the spatial uncertainty. Dose differences
in excess of this uncertainty would be displayed and ana-
lyzed. The gradient compensation method would remove
dose differences that might be due to the spatial uncertainty.
Presumably, the remaining differences would not be due to
spatial errors and the physicist could evaluate the magnitude
and clinical relevance of those errors.
The normalized agreement test (NAT) values and NAT
index were defined by Childress and Rosen.54 The NAT
index represented the average deviation from the percent dose
difference (DDm) and DTA criterion (Ddm) for every pixel
calculated, ignoring measurement areas having errors less
than a set criterion. They developed an algorithm that started
with computing the dose difference and DTA values. If the
dose difference for a point was less than the criterion, the
NATvalue was set to zero. If the DTA value was less than the
criterion, the NATwas set to zero. If the calculated dose was
less than 75% of the maximum calculated dose, the pixel
was assumed to be outside the PTV, and if the measured dose
was less than the computed dose, the error was assumed to
have no biological significance so the NAT was again set to
zero. If, on the other hand, the measured dose was greater
than the computed dose, or if the percent dose was greater
than 75%, the NAT value was computed as Dscale (d  1),
where d was the lesser of the ratios ABS DD=DDmð Þ or
Dd=Ddm, and Dscale was the greater of the computed or mea-
sured dose at the pixel of interest divided by the maximum
computed dose.
Bakai et al.53 developed a dose distribution comparison
tool based on gradient-dependent local acceptance thresh-
olds. The method took into account the local dose gradients
of a reference dose distribution for evaluation of misalign-
ment and collimation errors. These contributed to the maxi-
mum tolerable dose error at each evaluation point to which
the local dose differences between comparison and reference
data were compared. They identified two weaknesses of the c
test that they were addressing. First, that with an exhaustive
search, the c tool would take a considerable amount of time
to calculate, especially for 3D dose distributions. Second,
interpolation would be required if the dose distribution spac-
ing was insufficiently fine. They concluded that the search
process inherent in the c evaluation should be avoided and so
they defined an alternative process.
First, the dose axis was rescaled to units of distance by
multiplying the dose by the ratio of the DTA to dose differ-
ence criteria. Without interpolation, for relatively large grid
spacings and steep dose gradients, the tool overestimated the
value of c. The difference between the evaluated and refer-
ence doses was divided by a quantity called s0 which was
related to the local dose gradient, resulting in the dose distri-
bution comparison tool v. They compared dose distributions
calculated using the v and c tools and showed both methods
gave essentially the same results, however, the calculation of
v was more efficient than the calculation of c.
2.G. Practical considerations
Users of the c tool should understand its performance in
some detail. While the mechanics of the calculation are rela-
tively straightforward, there are operational details that can
reduce its effectiveness and accuracy.
2.G.1. Normalization
Normalization plays a critical role in the interpretation of
dose comparison results. The dose difference criterion is a
case in point. The dose difference criterion is typically
described as the percentage of the maximum dose for one or
both of the dose distributions being compared (global nor-
malization), or the percentage of the prescription dose. It also
can be described as a local dose percentage (local normaliza-
tion). Specifically in global normalization, the dose differ-
ence between any measured and calculated dose point pair is
normalized using the same value for all point pairs, often the
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maximum planned dose point. On the other hand, in local
normalization, the dose difference for all point pairs is nor-
malized to the planned dose at the local point. Selecting the
local normalization allows one to have the same relative toler-
ances in the target and critical structure volumes. However, it
will also cause the low-dose regions to have unrealistic dose
accuracy requirements.
The process of selecting the normalization involves com-
promises that are based in part on the differences between the
patient and phantom geometries. Ideally, one would like to
have clinically relevant criteria. The target volumes will
receive nearly homogeneous doses in composite delivery,
which are also near the maximum dose. Criteria for dose
accuracy within the target volume can be straightforwardly
defined, say at 3%, because the choice of using global vs.
local normalization will make little difference when the target
is concerned. However, the phantom and target shapes are
different, so the dose level and dose heterogeneity in the
phantom measurement will be different than the calculation.
One way to manage the difference in target shapes is to recon-
struct the dose in the patient using the measured data and thus
determine dose delivery and calculation errors in the patient
geometry (see Section 4.E.). This allows the c passing
thresholds to be clinically guided.
The problem is compounded when determining critical
structure dose tolerances. The dose difference criterion would
ideally be customized for each organ and the dose level found
in that organ. For example, the dose tolerance in the spinal
cord for a predicted cord dose of 45 Gy could be tighter than
the tolerance when the expected cord dose was 20 Gy. This
would allow the physicist to select clinically relevant criteria,
so they would detect only clinically relevant errors. However,
changes in dose gradients and absolute dose distribution dif-
ferences between the measurement and calculation within the
organ make the process of selecting organ-specific dose dif-
ference criteria more difficult. Also, such a comparison
between the measurement and calculation is only possible for
composite type delivery. Furthermore, customizing the dose
difference criterion for each organ with the commonly used
IMRT QA methods is currently not feasible, especially with
the uncertainties from the calculated beam penumbra near
inhomogeneities.
Like the dose difference criterion, the DTA criteria can
also be varied as desired. The concept of the allowance of
spatial dose errors comes from the reality that there are
always spatial uncertainties in patient setup and in internal
tumor and organ positions. Like dose errors, the DTA should
be a function of the clinical necessity of placing steep dose
gradients. These can be functions of both organ and dose.
For example, the DTA criterion for the dose gradient near the
spinal cord might be tighter than the DTA criterion for non-
critical normal tissues. Steep dose gradients often exist in
such tissues for fixed-gantry IMRT due to the entry or exit
fluence, yet the absolute spatial accuracy of those gradients
might not be clinically important. Discovering where these
dose gradient errors are going to be located in the patient
with the commonly used IMRT QA methods is difficult.
2.G.2 Spatial resolution
Spatial resolution has a great impact on the accuracy of
comparing dose distributions. As shown in Low et al.,43
without interpolation, the spatial resolution of the evaluated
distribution impacts the accuracy of the c calculation. Fig-
ures 5(a) and 5(b) show representations of a 1D dose distri-
bution in a steep dose gradient region. The distribution in
Fig. 5(a) is drawn such that the evaluated dose point closest
to the reference point is closer than any interpolated points.
Figure 5(b) differs from 5(a) in that the closest evaluated
dose point lies farther than the interpolated evaluated dose
distribution. Without interpolation, the determination of c in
this case would be greater than the closest distance of the
interpolated distribution. The error in the c calculation is a
function of the local dose gradient, the spacing between eval-
uated dose points, and the DTA criterion. Coincidentally, in
clinical radiation therapy, the spacing of measured or calcu-
lated doses is typically similar to the DTA criterion. For
example, many dose distribution calculations are conducted
on 3 9 3 9 3 mm3 grids, while the DTA criterion is often
3 mm. When the dose spacing and DTA criteria are similar,
the calculated error in c in steep dose gradients is large if no
interpolation is used. Assuming the dose difference is 0 in
the c calculation, the maximum error in c is roughly the ratio
of the spacing to the DTA criterion, so for example c will be
accurate to within 0.33 in a steep dose gradient region if the
spacing resolution ratio is 3:1. Therefore, a good rule of
thumb is that the resolution of the evaluated dose should be
no greater than 1/3 the DTA criterion. Interpolation can be
used to satisfy this rule. Not following this rule may degrade
dose distributions comparison accuracy.
This problem with spatial resolution had been assumed to
be significant only in the case of steep dose gradients. How-
ever, as shown in Fig. 5(c), when the evaluated dose distribu-
tion has a low-dose gradient region, similar errors can occur
if the location of one of the evaluated points does not coin-
cide with the reference point. Interpolation can reduce these
errors, but decrease the c calculation speed performance. Ju
et al.55 described an algorithm that reduced the interpolation
to a geometric problem. They proposed that each evaluated
dose distribution line, surface, or hypersurface (for 1D, 2D,
and 3D dose distributions) be subdivided into simplexes,
namely the representations of line or surface elements with
the smallest possible number of vertices. These constituted
line segments, triangles, and tetrahedra. When this subdivi-
sion was completed, the closest distance between the refer-
ence point and each simplex could easily be computed using
only matrix inversion. This sped up the process of calculating
c considerably as well as caused each calculation to be
implicitly linearly interpolated, removing the errors caused
by coarse evaluated dose distribution spacing.
2.G.3. Interpretation
Both the dose difference and DTA criteria can also be used
as universal error bars when comparing two measurements.
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The DTA criterion can be used to allow for measurement posi-
tioning error, for example positioning a phantom to the lasers,
and the ability to position film within a phantom.
While the ideal method for setting the dose difference and
DTA criteria would be organ and dose specific and based on
heterogeneous phantoms mimicking patient geometries, this
is not currently practical. One simple way of managing the
current standard of practice is to apply dose thresholding for
the c analysis. The doses smaller than a user-selected value
are not included in the c or other analyses. This allows the
user to focus on greater, clinically relevant doses.
Two-dimensional dose distributions can have thousands of
points being evaluated (a typical 20 9 20 cm2 film scanned
with a 0.5 mm2 resolution yields 160,000 points). There are a
few ways of reviewing the resulting comparison data. The
dose difference and c distributions can be presented as iso-
maps or colorwashes. The c distribution can also be summa-
rized by a c histogram.
The pass/fail criteria are selected in advance of the c calcu-
lation, but care should be taken when reviewing the c results.
In many cases, some points will not pass the c test and using
the exact number that can pass as the sole determinate of qual-
ity is challenging and may not yield clinically useful results. A
point that fails may not indicate a severe problem. Most of the
time, the c criteria are fairly strict. One of the advantages of
the c distribution is that it provides an indication not only that
the point failed, but by how much. A c value of 1.01 is indica-
tive of a failure but for a 3% dose difference and 3 mm DTA,
a c value of 1.01 could indicate a dose difference of 3.03% in
a low-dose gradient region or a DTA of nearly 3.03 mm in a
steep dose gradient region. Both of these are examples of fail-
ures, but failures that exceed tolerances by 0.03% and
0.03 mm in the low and steep dose gradient regions, respec-
tively. A point that fails the c test by 0.03% or 0.03 mm needs
to be considered differently than a point that fails by a substan-
tially wider margin. Therefore, the user should look not only at
the percentage of points that fail, but also make an analysis of
the maximum c value, the percentage of points that exceed a c
value of, say 1.5, the c histogram and possibly other statistical
values. Examining c calculations with different dose
difference/DTA criteria, e.g., 4%/3 mm, 3%/3 mm, 3%/
2 mm, 2%/3 mm, and 2%/2 mm . . .etc., can also help the user
understand the sources of discrepancies and their impact.
Without dose comparison statistics specific to tumor or
organ systems, one needs to remember that any histogram or
statistical analysis neglects the spatial information. It should be
noted that the c test could underestimate the clinical conse-
quences of certain dose delivery errors when the entire dose
distribution is evaluated together. This was demonstrated in
the work of Nelms et al.48 where the specific dose delivery
error they evaluated caused the high-dose regions to be deliv-
ered outside of the c tolerance while the dose delivery accu-
racy for lower doses was within tolerance. This correlation of
dose error and dose meant that the errors were clustered in the
high-dose region, which corresponded to the tumor. A compar-
ison of the dose-volume histograms clearly showed a system-
atic discrepancy between the dose distributions in the target,
while the c statistics (relative numbers of points with c > 1)
appeared to be clinically acceptable. Another reason for the
acceptable c statistics was that the ratio of tumor to irradiated
volumes was very small, so even if the tumor is incorrectly
irradiated, the fraction of points that failed the c test might also
be small. This highlights the fact that: (a) c statistics should be
provided in a structure by structure basis and (b) the c distribu-
tion should be reviewed rather than relying only on distilled
statistical evaluations such as c histograms.
3. REVIEW OF MEASUREMENT METHODS
Several methods can be used to perform pretreatment
patient-specific IMRT verification QA measurements as
shown in Fig. 6. The most common methods in clinical prac-
tice are: (a) true composite (TC), (b) perpendicular field-by-
field (PFF), and (c) perpendicular composite (PC). For each
of these methods, the patient’s plan is recomputed onto a
phantom that exists both physically and within the planning
system. The TPS calculates the dose in the phantom (hybrid
plan) in the same geometry as for the subsequent measure-
ments.56 In a survey on planar IMRT QA analysis with 2D


























FIG. 5. Example of the c calculation error when the evaluated dose distribution spatial resolution is relatively coarse with respect to the DTA criterion. (a) The
calculation is correct. (b) The calculated value is greater than what would be calculated if interpolation was used. (c) Evaluated dose distributions with low-dose
gradients can have the same error if the evaluated pixel locations differ from the reference pixel.
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respondents reported using the field-by-field method and
58% performed absolute dose analysis. The survey results
showed that 76.3% of the clinics used 3%, 2.9% used 4%,
and 15.1% used 5% dose difference limits. In addition, it was
noted that 82.7% used 3 mm, 5.0% used 4 mm and 2.6%
used 5 mm DTA limits. They reported 34.5% used 0–5%,
36.7% used 5–10% and 28.8% used ≥10% standard lower
threshold dose limits. In the following sections, each method
is described along with the types of data that are obtained.
Further, the pros and cons of each method are discussed. For
all methods described below, the recommendations of TG-
12017 can be utilized for dosimetric methods.
3.A. True composite (TC)
The TC method simulates the treatment delivery to the
patient. The radiation beams are delivered to a stationary
measurement device or phantom on the couch using the
actual treatment parameters for the patient, including MUs,
gantry, collimator, couch angles, jaws, and MLC leaf posi-
tions. The method has been used most often by physicists per-
forming film dosimetry although more recently, diode and
chamber array devices have been used. Typically with film
dosimetry, an ion chamber (IC) is placed inside the phantom
and irradiated along with one or more sheets of ReadyPack
EDR2 (Eastman Kodak Company, Rochester, NY, USA) or
Gafchromic EBT film (International Specialty Products,
Wayne, NJ), providing simultaneous measurements of abso-
lute IC dose and relative planar doses58–62 [Fig. 6(a)]. The
measured IC reading can be converted to dose by taking the
ratio of a reference field reading to a known dose (e.g.,
10 9 10 cm2 at reference depth) in phantom.
The film or detector array is usually positioned in a coronal
orientation on the couch [Fig. 6(b)] but can be in a sagittal
orientation [Fig. 6(c)] (or transverse plane for film) or a
rotated plane. Because the recorded doses are from all the
beams in the plan at their planned positions, the dose distribu-
tion mimics the dose distribution inside the patient, distorted
and modified only by the difference between the patient and
phantom external contours and a lack of heterogeneities in the
phantom. Within the film or detector array, uniform high-dose
regions will be present along with similar dose gradients and
low-dose regions that occur in the patient’s plan.
Detector arrays designed for perpendicular irradiation
have been used to integrate the dose during the TC irradia-
tion. Additional phantom material surrounding the array has
been used to obtain at least 5 cm depth in all directions.
Since the 2D arrays are designed for perpendicular measure-
ments, the array detector’s radiation response is angularly
dependent. This angular dependence is caused by beam atten-
uation from internal electronics, device encapsulation materi-
als, diode detector packaging materials, and air cavities.63–65
The diode array may have significant angular dependence
within 10° of the horizontal axis, primarily due to air cavi-
ties between detectors.64,65 The angular dependence may be
smeared out when using beams from many angles, such as
with VMAT delivery. However, caution should be taken when
using 2D arrays for IMRT QA when more than 20% of the
dose comes from the lateral direction.64 Another limitation
for diode or ionization chamber arrays comes into play for
non-coplanar beams, which can irradiate the active electron-
ics of the device for certain field sizes and beam angles.
Compared to film dosimetry, these ion chamber/diode arrays
have much lower spatial resolution. This becomes a disadvan-
tage in measuring doses of very small tumor volumes or with
steep dose gradients, as well as commissioning IMRT sys-
tems. It is important to note that with arrays, unlike films, an
independent IC reading is not essential because the QA anal-
ysis can be performed in absolute dose mode.
The measurement plane for a film or array can be placed
either inside the high-dose volume or in a plane that samples
doses received by a particular critical structure. A common
position for film is immediately anterior or posterior to the ion
chamber. The mean dose to the ion chamber volume (the
chamber volume is contoured in the planning system phantom)
as well as the 2D dose distribution in the same plane(s) as the
film or array is calculated. The percent relative differences
between the measured and calculated chamber doses are then
compared to the acceptance criteria. The film dose image is
registered to the 2D TPS dose image using pin pricks on the
film or other fiducial marks which relate the film to the linac
isocenter while the array dose image is aligned to the planning
system dose image by deliberate positioning of the isocenter
relative to the array origin. After registration, an isodose over-
lay and/or c analysis is performed.8,66 If an IC is used, it is
often placed at the isocenter when it lies in a uniform high-
F1, F2, ... , FN


















FIG. 6. (a) True composite (TC) delivery on a phantom with an IC placed at a specific depth and a radiographic film at a coronal orientation. (b) TC delivery on
a stationary 2D array device placed in the coronal direction on the treatment table. (c) TC delivery on a stationary 2D array device placed in the sagittal direction
on the treatment table. (d) Perpendicular field-by-field (PFF) or perpendicular composite (PC) delivery on a stationary 2D array device placed in the coronal
direction on the treatment table. (e) PFF or PC delivery on 2D array device mounted on the treatment head.
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dose region. If the isocenter lies in a nonuniform dose region,
the IC can be placed away from the isocenter in a more uni-
form dose region. Note that an ion chamber reading alone
without a 2D dose plane measurement is not sufficient for
detecting errors other than at that single point.39
3.A.1. Advantages and disadvantages
There are three main advantages to the TC method. The first
is that the measurement includes inaccuracies of the gantry,
collimator, couch angles, and MLC leaf positions with gantry
angle (gravity effects) as well as the attenuation of the couch
top. The second advantage is that the resulting planar dose dis-
tribution is closely related to the dose that will be delivered to
the patient, so that the relationship between the high-dose
region and organs at risk lying in the same plane can be
assessed. Third, there is only one dose image to analyze (per
plane of interest). The main disadvantage is that portions of
many beams will not traverse the film or detector plane. This is
particularly true if the film/detector plane is transverse and irra-
diated by only one pair of MLC leaves. Thus, not every part of
every beam is sampled. However, detector devices designed to
measure VMAT beams such as ArcCheck (Sun Nuclear Cor-
poration, Melbourne, FL, USA) or Delta4 (ScandiDos, Upp-
sala, Sweden) generally sample the entire beam area.
3.B. Perpendicular field-by-field (PFF)
In this method, the gantry is fixed at 0 degree (pointing
down) for all beams and the collimator is fixed at the nominal
angle [Fig. 6(d)]. PFF is used most often with diode or cham-
ber arrays although film and EPIDs have been used as well.
Gantry mounting fixtures are available for some arrays, so
that the actual gantry angle can be used during irradiation to
include the gravity effects on the MLC leaves [Fig. 6(e)]. The
TPS calculates the dose to the same plane as the measure-
ment detector and that dose plane is registered to the mea-
sured dose image using pin pricks or other fiducial marks in
the case of film or by aligning the array dose image to the
planning system dose image by their common center in the
case of 2D arrays. A comparison of the planned vs. measured
dose is then performed for each field. These analyses can be
performed in absolute dose mode, so that an independent IC
reading is not needed. Isodose and profile overlays are also
used to compare the dose distributions. When an IC is used,
similar to TC delivery, the chamber is typically placed at the
isocenter in a uniform high-dose region.
3.B.1. Advantages and disadvantages
The advantage of the PFF method is that it samples every
part of every field as the dose from each of the IMRT fields is
delivered and analyzed separately. Field-by-field analysis may
reveal some subtle delivery errors. It prevents the dose wash-
out that can occur in a composite measurement geometry
when under-dosing in some areas in part of one beam may be
compensated by an increased dose in the same region by
another beam. PFF may be more stringent because the dose
distribution from each beam is so highly modulated, small dif-
ferences in dose and its location can cause large differences in
the analysis result. To a greater extent than for TC, the agree-
ment between the calculations and measurements is more
dependent on the normalization values for relative dose analy-
sis or shifts from the initial registration (Table I). In addition,
the significance of a summation of discrete dose errors in each
beam image, which commonly occurs, is not generally known.
In this situation, analysis results can be misleading as sug-
gested by a number of studies which have found a poor to
moderate correlation between field-by-field 3%/3 mm DTA
results and the actual measured to calculated 3D dose differ-
ences in the patient or phantom.48,67–70 While these findings
may cast doubt on the value of these measurements, it empha-
sizes that the method and results should be carefully inter-
preted. It also emphasizes that clinical interpretation of QA
failure results is a challenging process.
3.C. Perpendicular composite (PC)
The PC method is similar to the PFF method described
above in (b), except that the dose is integrated for all the per-
pendicular fields, resulting in a single dose image for analysis
[Fig. 6(d)], and making the method faster than PFF. The
same measuring equipment and analysis methods are used.
3.C.1. Advantages and Disadvantages
The advantage of the PC method is that all portions of each
beam are incorporated in a single image. EPIDs can be used if
each beam’s dose image is acquired separately and then added
together later. Using the EPID to obtain an integrated image
for VMAT is considered PC. The disadvantage is that the
method may mask some dose delivery errors, such as those in
the scattered regions, and dose errors from any one beam,
within the composite, may be obscured by the superposition of
the other beam doses.71 Further, for VMAT delivery the dose
rate variation vs. gantry may be obscured using this method
and errors caused by using uniform dose rate delivery vs.
nonuniform dose rate delivery were not caught using PC. The
TABLE I. For field-by-field c analysis based on relative dose, the passing rate
is highly dependent on the location of the point of normalization. This table
from commercial software system shows passing rates based on either points
that maximize the passing rate, the central axis point, or the maximum dose
point.
Normalization point X,Y
coordinates (mm) Pass Fail %Passing
25,25 263 3 98.9
20,30 259 7 97.4
45,5 248 18 93.2
30,30 251 19 93.0
25,35 244 20 92.4
0,0 (CAX) 221 79 73.7
25,35 (Max) 244 20 92.4
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dose distribution is unrelated to that in the patient and can be
difficult to interpret clinically, and may not have large areas of
uniform dose despite the compositing effect.
3.D. Method selection
It is difficult to choose one of the three methods as clini-
cally preferable for IMRT QA. The clinically preferred
method would be the one that best identifies significant dif-
ferences between delivered and calculated doses. The TC
method has the advantage of providing a 2D dose slice out of
the 3D dose distribution while the PFF method only provides
information on each beam with limited ability to interpret the
3D dose consequence of regional errors in a single beam. Of
course, if the per-field c result is perfect for every beam
(100% passing) using a specific acceptance criteria, then it is
highly likely that the delivered dose will closely match the
calculated dose, although Nelms et al. showed that even that
scenario is not always true.48 The PC method has the distinct
disadvantage of potentially masking errors due to the summa-
tion. Regardless of the advantages of any particular 2D based
method, none of the methods discussed provides information
about the 3D dose deviation in the patient.
When comparing the c failure rate results for the same
plan tested by each of the three methods, little if any correla-
tion has been observed. For example, AAPM TG-11916
reported confidence limits as baseline values for IMRT com-
missioning based on the measurement results for a set of test
cases from several institutions. The cases were designed to
test overall IMRT planning and delivery accuracy. Using the
same set of test plans, the TG-119 report showed a difference
in the confidence limit of 12.4% for TC vs. 7% for PFF.16
This means that care must be exercised when attempting to
relate results from one clinic using one method to that of
another clinic that employs a different method.
4. REVIEW OF METHODOLOGIES FOR ABSOLUTE
DOSE VERIFICATION
A number of techniques can be used for absolute dose ver-
ification. Single-point measurements such as those obtained
using individual ICs can be considered dose distributions of
zero dimension. Radiographic and radiochromic films, diode
arrays, chamber arrays, and EPID provide 2D distributions,
and 3D dose distributions are measured within gel and other
3D dosimeters.
Absolute dose can be verified using point-dose techniques
and 2D measurements. Hybrid versions of 3D measurement
techniques have recently become commercially available for
clinical use. The AAPM TG-120 report thoroughly describes
the tools and measurement techniques used for both IMRT
commissioning and patient-specific measurements.17 The
methodologies are briefly reviewed below. The reader is
directed to the TG-120 publication for more specific informa-
tion.17 Film dosimetry, including calibration, scanning, and
other aspects are not discussed here; the reader is instead
referred to the report from AAPM TG-69.72
4.A. Single-point (small-averaged volume) method
The most basic measurement that can be made for patient-
specific plan verification is a point-dose measurement. Typi-
cally, cylindrical ICs and stylized QA phantoms are used for
these measurements. Though commonly referred to as point
measurements because a single number is reported, these
measurements are actually small-volume measurements over
the volume of the chamber. They can be used to verify that a
certain MU setting results in the correct absolute dose. Verifi-
cation of absolute dose can be for either the target or for criti-
cal structures, depending on the chamber placement in the
QA phantom.
Chamber volumes may vary from 0.007 to 0.6 cc, and
leakage current must be adequately taken into considera-
tion.17,73 The chamber should be placed in a region of uni-
form dose and should have adequate spatial resolution. A
good rule of thumb is that the maximum and minimum doses
across the IC (as reported in the TPS dose statistics for the IC
volume) should be within 5% of the mean chamber dose to
minimize the effects of volume averaging over a gradient
region. The size of the IC is not particularly critical and one
can make arguments for using a 0.6cc chamber or using a
smaller chamber size.74 Specifically, the potential problem
with small volume chambers is that to the extent there are
dose gradients near the chamber, small positioning errors will
cause large apparent measured dose differences relative to the
treatment plan dose. The larger volume chamber will average
these gradients and be less sensitive to positioning errors as
long as the chamber volume has been correctly contoured in
the TPS.
Clinically significant doses such as the dose in the PTV or
in an OAR region should be measured. When possible, the
measured dose should be compared to a planned dose to the
volume of the chamber, instead of a point dose that corre-
sponds to the middle of the active volume of the chamber as
depicted in the QA plan. When a chamber is selected for
patient-specific QA, a cross-calibration technique can be
used to determine the dose response of the chamber cho-
sen.17,75
4.B. 2D methods
Two-dimensional measurements can be made to obtain a
more representative picture of the dose delivery distribution,
corresponding to a planar dose. Commercially available
dosimeters that fall in the 2D methods category include ion-
ization chamber arrays, diode arrays, EPIDs, and film. They
are typically used to measure the 2D dose distributions
associated with a specific IMRT field. These detectors can
provide relative dose comparisons against the QA plan.
They can also be calibrated to report absolute dose mea-
surements but caution should be exercised when using
EPIDs and film as they are not ideal absolute dosimeters.
Calibration and commissioning should be performed before
use, following the vendor recommendations and any pub-
lished guidelines. Planar dose distributions can be exported
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from the TPS at the plane of measurement and an absolute
or relative dose comparison can be performed against the
measurement results from the array. While 2D planar arrays
are typically used for single field measurements, not for
measuring the TC IMRT plan,17,76 rotational devices have
been used for measuring the TC VMAT plans and some
arrays have been inserted in slab phantoms for rotational
IMRT QA measurements.
Film can also be used as a 2D measurement device. Both
radiographic (e.g., EDR2) and radiochromic (e.g., EBT2)
films have been used. Care must be taken to accurately con-
vert the optical density to dose from a film measure-
ment.72,77–79 Commissioning of each film batch should
include characterizing the dose response, sensitivity, and uni-
formity of the film. The amount of noise in the film should
be considered when determining the dose to be delivered to
the film. Radiographic film requires a dark room and a pro-
cessor. Radiochromic film has the advantage of being less
light sensitive than radiographic film, but still must be stored
in a light-proof envelope and read at a particular time after
exposure to account for the reverse fading effect. For plans
delivering more than about 7 Gy per fraction, the MUs may
have to be proportionally reduced to avoid EDR2 film satura-
tion,62 while Gafchromic EBT2 films have shown to work for
doses of 1 cGy–10 Gy in the red color channel, and up to
40 Gy in the green color channel. Both types of film mea-
surements can be normalized to a dose reading from an IC to
avoid some of the uncertainties in obtaining absolute dose
from film light transmission readings.
Although more difficult to use, film can measure TC planar
dose distribution with a higher spatial resolution than detector
arrays. Film may have the ability to reveal clinically relevant
differences between treatment plans and deliveries that might
not be otherwise detected using only per-field measurements.
However, detector arrays measure the doses at the individual
detector locations more accurately than film due to the uncer-
tainties associated with film processing and densitometry.
4.C. 3D methods
Three-dimensional measurement methods, such as 3D gels80
and PRESSAGE dosimeters,81,82 are used to provide a TC mea-
surement of the delivered IMRT/VMAT dose in a 3D high-
resolution volume. Three-dimensional volume gel dosimeters
are becoming more refined and have been used by several
research groups in an investigational clinical setting83,84 but
they are not yet widely available for patient-specific QA mea-
surements.85 Although the published studies show the versatil-
ity and the added value of gel polymers as true 3D dosimeters,
there remain limitations with this technique, including the sta-
bility and manufacturing of the gel, the calibration of the sys-
tem, the reading of the gel after it has been irradiated and the
fact that the gel can only be used once. In addition to gel
dosimeters, some newly developed detector arrays that have
nonplanar geometries are capable of measuring both per-field
and composite dose for both IMRT and VMAT QA,86–90
although not in a true 3D, high spatial resolution volume.
4.D. Comparison of single-point, 2D and 3D
methods
The strength of point-dose measurements with ICs is that
they can be used to verify the accuracy of the MU calcula-
tions conducted by the TPS because they measure the abso-
lute dose rather than just the relative dose. These measured
doses typically have smaller uncertainty than film or detector
array measurements and can also be used when scaling rela-
tive 2D measurements. The limitation is that ICs measure the
dose at only one point (actually a small volume-averaged
region), and while this measured dose is compared against
the treatment plan, it does not provide enough information to
validate overall plan accuracy.
Two-dimensional and three-dimensional dose measurement
methods give a more comprehensive picture of plan delivery
than point-dose measurements. Although initially the intent
was to use the 2D arrays for per-field dose comparisons, most
of the manufacturers have recently incorporated directional
response corrections for the detectors. Two-dimensional
arrays, although an improvement over the single-point method,
are limited to a dose comparison in a plane and not a 3D vol-
ume. Because 2D or 3D measurements have the ability to
show relative dose distributions, it can be tempting to ignore
the absolute dose information they measure. When they are
used in this manner, considerable differences between dose
delivery and dose calculation may go undetected. Therefore,
2D and 3D arrays should always be calibrated and used to
measure the absolute dose. The calibration methods and fre-
quency should follow the recommendations from the manufac-
turers. The array calibration frequency will also depend on the
usage of the array device. A dose calibration measurement
compared against a standard dose should be performed before
each measurement session to factor the variation of the detec-
tor response and accelerator output into the QA measurement.
4.E. Reconstruction methods
The quantitative comparison between the measured dose
in a phantom and the corresponding QA treatment plan has
been traditionally based on indices such as the DTA, dose
difference and the c index. New developments in the QA
devices and their associated analysis software modules allow
the conversion of the measured dose distribution data to 3D
absolute dose distributions in the patient anatomy. Thus, a
more clinically relevant comparison between the clinical
treatment plan, including dose distributions and DVHs for all
delineated structures, can be made against the treatment plan
reconstructed from the measurements.
There are several commercially available approaches for
the 3D reconstruction methods:
4.E.1. Forward calculation algorithm
This method treats the measurement data as a fluence
map. The software uses the CT data along with a forward cal-
culation algorithm such as pencil beam or collapsed
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cone,91,92 to reconstruct the 3D dose in the patient. The mea-
surement data can be from an EPID,93 2D diode or 2D cham-
ber arrays.91,94,95 In essence, these implementations use the
patient-specific beams that are then delivered to the detector,
typically in the absence of a phantom or patient. The mea-
sured data are corrected for the response of the detector and
subsequently used as the input fluence map to a forward dose
calculation in the patient anatomy. This operation requires an
independent dose calculation platform91,92 but can also be
done using the TPS itself,41 thus removing any ambiguities in
the analysis that may result from differences in dose calcula-
tion algorithms between the TPS and the independent calcu-
lation platform. However, using the TPS dose calculation
algorithm for both calculations may mask out beam modeling
errors or algorithm limitations for IMRT beams.
4.E.2. Plan dose perturbation
Plan dose perturbation (PDP) uses the difference between
the measured and TPS calculated dose in phantom to perturb
the 3D TPS calculated patient dose and create a corrected 3D
dose distribution in the patient geometry. This method does
not require a forward calculation algorithm. It relies on the
measurement to create the perturbation matrix for correcting
the TPS generated plan.69,70,96–98 These measured data can
be obtained using 2D and 3D arrays.
4.E.3. 3D reconstruction in phantom
A rotating phantom with an embedded 2D array was
recently introduced commercially, such that the array is
always perpendicular to the beam axis for VMAT deliveries.
A 3D dose distribution reconstructed from measurements is
used for comparison with the patient QA plan.99 The recon-
struction algorithm is based on percent depth dose curves
entered to the system as part of the commissioning process.
While the dose is reconstructed in 3D, it is done in the phan-
tom and not in the patient CT data.
4.E.4. Per-fraction patient transmission-based QA
This is an EPID-based measurement method that collects
data during patient treatment to verify delivery. Images are
collected while the patient is treated, and are used to recon-
struct dose in the patient for each treatment. The measured
transmission fluence can be corrected (e.g., for the EPID
response and for the scatter from patient) and backpro-
jected.92,100,101 The deconvolved and backprojected primary
fluence can then be forward transported through the patient
anatomy and the 3D dose can be calculated in the patient and
compared against the treatment plan for each fraction.
5. REVIEW OF REPORTED IMRT MEASURED VS.
CALCULATED AGREEMENT
Patient-specific IMRT QA has been performed and ana-
lyzed in several modes: (a) an absolute dose to a detector,
measured in a high-dose region with a low-dose gradient,40
(b) absolute planar dose, either normalized to a locally calcu-
lated point dose, the global calculated maximum dose of the
plane, or the maximum dose of the entire treatment plan,17
(c) a DTA measure,32,50 (d) c analysis.43,51
The reported IMRT QA agreement between measurements
and calculations, including absolute dose agreement and c
passing rates for various tolerance limits, is summarized in
Table II. Table II shows absolute dose measurements with ICs
agreeing with expected values to within 5% and 2D measure-
ments having c pass rates > 90% using 3%/3 mm DTA (glo-
bal normalization).102,103 Furthermore, recent studies have
reported nearly 100% passing rates for 3%/3 mm64,104–106 and




With fixed-gantry IMRT delivery, early patient-specific
IMRT QA methods were performed using single ICs com-
bined with a few other selected point doses40,75 and/or one or
two planar films.107 With the availability of commercial
IMRT QA devices, the elimination of radiographic film and
film processors, and the need for time efficient methods, the
majority of IMRT QA is currently conducted using 2D diode
or ionization chamber array devices.76,108–110 If an electronic
portal imaging device (EPID)111–114 is used, then no addi-
tional dosimetry equipment may be needed.
Based on an early generation IMRT treatment planning sys-
tem with a pencil beam calculation algorithm, Dong et al.75
reported that a mean percentage difference between the calcu-
lated and measured point doses for 1591 points of 751 clinical
IMRT cases was 0.37%  1.7%, with a range of the NAT
value was computed as 4.5% to 9.5%. Irradiating a head and
neck (HN) anthropomorphic phantom, 71 institutions out of
250 failed the initial credential test designed by Imaging and
Radiation Oncology Core (IROC) Houston using the criteria
of 7% for the TLD in the PTV and 4 mm DTA for the film in
the high-dose gradient area between the PTV and the OAR.33
A recent update of the IROC HN phantom irradiation study
reported the results from 1139 irradiations by 763 institutions
from 2001 to 2011.115 Of the irradiations, 81.6% passed the cri-
teria, 13.7% irradiations failed only the TLD criteria, 1.8%
failed only the film criteria, and 2.9% failed both sets of crite-
ria. Only 69% of the irradiations passed a narrowed TLD cri-
terion of 5%. The IROC data show that institutions who
were sufficiently confident in their IMRT QA planning and
delivery processes to participate in the RTOG IMRT trials, var-
ied in their capability to deliver the phantom-planned dose dis-
tributions. More importantly, the data show the significance of
performing patient-specific IMRT verification QA and empha-
size the importance of properly commissioning IMRT in both
the treatment planning and delivery systems.
From a single institution experience, Both et al.102 ana-
lyzed 747 fluence maps generated from three commonly used
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treatment planning systems and measured with a 2D diode
array using 6MV photon beams. They found for relative
doses that the average passing rate using 3%/3 mm with 10%
dose threshold criteria for prostate and other cases was
99.3%  1.41% and for HN cases was 96.22%  2.89%.
For absolute point doses, they found that the average percent-
age dose error for prostate and other cases was
0.419%  0.42% and for HN cases was 1.41%  1.1%. The
differences between the prostate/other cases and HN cases
were statistically significant.
5.A.2. Volumetric modulated arc radiotherapy
Partly due to its decreased delivery time compared against
static gantry IMRT, VMAT is becoming the preferred tech-
nique for IMRT delivery. In Teke’s116 study, ten clinically
acceptable VMAT treatment plans were calculated in a phan-
tom using a Monte Carlo (MC) dose calculation algorithm and
actual delivery log files. Measurements using a Farmer ioniza-
tion chamber (PTW-Freiburg, Freiburg, Germany) with an
active volume of 0.6 cc agreed with both MC and TPS calcula-
tions to within 2.1%. Analyzing the detailed machine log files,
they also confirmed that leaf position errors were less than
1 mm for 94% of the time and there were no leaf errors greater
than 2.5 mm. The mean standard deviations (SDs) in MU and
gantry angle were 0.052 MU and 0.355°, respectively, for the
ten cases they analyzed. This study demonstrated that accurate
VMAT delivery and stable machine performance were achiev-
able. As a result, expectation of good agreement between pre-
dicted and measured dose for a VMAT delivery is warranted.
Many investigators have reported on experimental valida-
tion of VMAT delivery using various 1D, 2D and 3D
TABLE II. IMRT QA measurement results reported in the literature. Results include absolute point-dose agreement and c passing rates for various tolerance
limits.
Author year Delivery technique Dosimeter Number of irradiation Reported results
Dong 200375 Fixed-gantry and
serial tomotherapy
IC 751 cases and 1591
measurements
0.37%  1.7% (4.5% to 9.5%)
Both 2007102 Fixed-gantry 2D Diode array 747 fields 3%/3 mm relative: 96.22%  2.89% (HN), 99.30%  1.41%
(prostate and other sites); absolute point dose error:
1.41%  1.10% (HN), 0.419%  0.420% (prostate and other
sites)
Ibbott 200833 Not specified Film, TLDs 250 (multi-institution) 179 (72%) pass (7%/4 mm absolute/global)
Molineu 2013107 Not specified Film, TLD 1139 irradiations, 763
institutions
929 (81.6%) pass (7%/4 mm absolute/global)
Basran 2008108 Fixed-gantry 2D diode array 115 plans 3%/3 mm absolute/global: 95.5%  3.5% (HN),
98.8%  2.0% (GU), 97.3%  1.6% (lung)







High-dose point: 0.2%  2.2%; low-dose point:
0.3%  2.2% (composite); per-field: 97.9%  2.5% (3%/
3 mm absolute/global); composite film: 96.3%  4.4% (3%/
3 mm absolute/global)
Geurts 2009109 Tomotherapy 3D diode array 264 plans 3%/3 mm: 97.5%, range 90.0–100%; absolute/relative or global/
local not indicated




IC: 3%; planar: >90% (3%/3mm absolute/global); range or SD
not given
Masi 201164 VMAT IC, film, 2D diode
array, 2D IC array
50 plans IC: 1.1%  1.0%; electronic planar: >97.4% (3%/3 mm or 3%/
2 mm absolute/both global and local), range 92.0–100%;
EDR2: 95.1%, range 83.0–100%; EBT2: 91.1%, range 80.0%–
98.5%
Bailey 2011103 Fixed-gantry 2D diode array,
EPID
25 prostate fields, 79
HN fields
2%/2 mm absolute/global: 80.4% (prostate), 77.9% (HN); 2%/
2 mm absolute/local: 66.3% (prostate), 50.5% (HN); 3%/3 mm
absolute/global: 96.7% (prostate), 93.5% (HN); 3%/3mm
absolute/local: 90.8% (prostate), 70.6% (HN)
Lang 2012104 Fixed-gantry or
VMATwith FFF
IC, Film, 3D
diode array, 2D IC
array
224 plans (52 plans
with IC)
99.3%  1.1% (3%/3 mm absolute/global); point dose: 0.34%
(2% for 88% of cases)
Mancuso 2012105 Fixed-gantry and
VMAT
IC, Film or 2D
diode array
TG-119 test cases IC: 0.82%  0.48% (IMRT) and 1.89%  0.50%
(VMAT); Film: 97.6%  0.6% for IMRT, 97.5%  0.8% for
VMAT (2%/2 mm composite, absolute/global); Diode:
98.7%  0.3% for IMRT and 98.6%  0.4% for VMAT (3%/
3 mm absolute/global)
Bresciani 2013106 Tomotherapy 3D diode array 73 plans Absolute global: 98%  2% (3%/3 mm), 92%  7% (2%/
2 mm), 61%  11% (1%/1 mm); absolute local (2 cGy local
threshold): 93%  6%(3%/3 mm), 84%  9%(2%/2 mm),
66%  12%(1%/1 mm)
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dosimeters, including a helical diode array, a biplanar diode
array and an ionization chamber array.64,89,117 VMAT deliv-
ery is available on commercial gantry-based linear accelera-
tors, with the properly installed software and hardware. The
key for accurate delivery is precise synchronization of MLC
motion, gantry motion, and dose rate adjustment (when
employed). During treatment planning, VMAT plans are dis-
cretized into many static beams, varying from 2 to 7 degrees
apart. Therefore, delivery accuracy and thus VMAT QA
results may depend on discretization resolution and plan
complexity. Feygelman et al.118 reported that when calculated
using 4 spacing, the overall mean dose errors at a single
position measured using an ionization chamber were
0.5%  1.4% and 0.3%  1.4% for the PTV and OAR,
respectively, using the TG-119 phantom geometries. The c
passing rate (3%/3mm), measured for absolute dose with a
biplanar diode array, was 98.2%1.6% (range 94.5–99.9%).
Using 6 control point spacing, highly modulated plans
exhibited large dosimetric errors [e.g., c (3%/3 mm) passing
rates below 90% and ion chamber point-dose errors of
6–12%], while simple cases had acceptable results.
Mancuso et al.105 performed a systematic comparison of
fixed-gantry IMRT and VMAT patient-specific measure-
ments using the TG-119 phantom geometries. They reported
2%/2 mm and 3%/3 mm average c passing rates of > 97%
and > 98%, respectively, for both IMRT and VMAT plans
with no statistically significant differences between the two
modalities. They suggested that it was appropriate to use
fixed-beam IMRT action levels for VMAT.
5.A.3. Flattening filter free IMRT
Flattening filters were designed to create homogeneous dose
distributions for conformal treatment plans. The flattening filter
significantly attenuates the dose rate and adds scattered dose.
For IMRT, inverse planning methods are used to generate non-
flat beams for treatment planning. The increased use of
hypofractionated treatments has resulted in the development of
flattening filter free beams to increase the dose rate and conse-
quently decrease treatment time, and to reduce the scattered
radiation that increases the total body dose. Inverse planning
methods are used for planning with these beams. Lang et al.104
presented pretreatment QA data for 224 cases from four cen-
ters, measured with different verification devices to assess the
reliability of flattening filter free beam delivery for IMRT and
VMAT techniques. They found excellent agreement between
dose calculation and dose delivery for these beams, with an
average passing rate of 99.3%  1.1% for IMRT and
98.8%  1.1% for VMAT using c tolerance limits of 3%/
3 mm. For 52 of the cases, a dose verification at a single posi-
tion was performed with an IC, either a PinPoint chamber or a
Farmer chamber, with a mean dose deviation of only 0.34%.
They found that the passing rate was independent of the maxi-
mum dose rate used during irradiation of the arc. However,
during irradiation of the arc, the passing rate decreased with
increasing ratio of the MU to the dose per fraction, indicating
that highly modulated plans had slightly worse QA results.
5.A.4. Tomotherapy
With Tomotherapy delivery (Accuray, Sunnyvale, CA,
USA), the dose delivery precision relies on synchronization
of the dynamic components including gantry, couch and
MLC.119,120 Broggi et al.121 reported that, over a 2-yr period
and based on monthly checks, gantry-couch synchronization
was better than 2 mm, and gantry-MLC synchronization was
within 1°. For the same period, dosimetric tests showed an
average rotational output variation of 0.01% (1 SD). It
was noteworthy that several groups reported a dose rate or
output variation of 1–2% during a treatment day or an IMRT
QA session.65,122,123 Consequently, the machine output fluc-
tuations were likely inherent in IMRT QA deliveries, which
should be considered when analyzing the IMRT QA mea-
surement data.
Phantom-based dosimetric measurements are recom-
mended by AAPM TG-148119 for both commissioning and
clinical use. According to TG-148, an ionization chamber
measurement is expected to agree with calculations to
within 3%; for planar dosimetry using criteria of 3%/3 mm
DTA, a c passing rate of at least 90% can be achieved.
Care needs to be taken with regard to the angular depen-
dence due to Tomotherapy’s rotational dose delivery. Com-
mercial electronic array dosimeters, made of either
ionization chamber or diodes, have an anisotropic dose
response as a function of beam incident angle.63,65,87
Geurts et al. reported their clinic’s experience with
Tomotherapy QA using a biplanar diode array dosimeter
for over 250 clinical cases including breast, HN, colorectal,
and prostate cancers.123 For c criteria of 3%/3mm, they
reported an average of 97.5% (range 90.0–100%) agreement
between calculations and measurements, suggesting both
the excellent measurement capability of advanced dosime-
ters and the delivery accuracy of Tomotherapy units. In
addition, a significant positive correlation between IMRT
QA and daily output QA was found, whereas there was no
correlation between the c passing rates with treatment vari-
ables such as PTV volume, fractional dose, field size, mod-
ulation factor, pitch, or off-axis distance.
5.B. Considerations when using the c test passing
rates for evaluation
In clinical practice, many centers use the c index51 to
avoid the oversensitivity of dose difference and DTA tests to
steep and low-dose gradient regions, respectively, as we dis-
cussed in Section 2. Some investigators,48,68 however, have
highlighted situations where the c index is insensitive in
detecting dose errors using single field measurements and
certain delivery errors such as incorrect leaf positions.
Yan et al.124 introduced random and systematic MLC leaf
position errors. With 3%/3 mm criteria and a 90% passing
rate, planar measurements using a 2D diode array with 7 mm
detector spacing were only able to detect leaf position errors
greater than 2 mm. Mu et al.125 analyzed twelve simple direct
machine parameter optimization (DMPO)-based plans with
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the total number of segments limited to 50 and five complex
plans generated using conventional two-step optimization with
≥ 100 segments. For a 1 mm systematic error, the average
changes in D95% were 4% for simple plans vs. 8% for com-
plex plans. The average changes in D0.1cc of the spinal cord
and brain stem were 4% in simple plans vs. 12% in complex
plans. They concluded that for induced systematic MLC leaf
position errors of 1 mm, delivery accuracy of HN treatment
plans could be affected, especially for highly modulated plans.
Kruse investigated the sensitivity of the fraction of points
that failed the c test with 2%/2 mm and 3%/3 mm criteria
using EPID and ionization chamber array measurements.67 He
used three HN treatment plans and created a second set by
adjusting the dose constraints to create highly modulated deliv-
ery sequences. The treatment plans were computed on a cylin-
drical phantom, and EPID and ionization chamber array
measurements were acquired and compared against calcula-
tion. They found that the highly modulated plans with aggres-
sive constraints had many points that differed from the
calculations by more than 4%, with one point differing by
10.6%. Using the ionization chamber array, the fraction of
points that passed the 2%/2mm criteria were between 92.4% to
94.9% for the original plans and 86.8% to 98.3% for the highly
modulated plans. Similar results were found using the 3%/
3 mm criteria with the same ionization chamber array. They
concluded that the fraction of pixels passing the c criteria from
individually irradiated beams was a poor predictor of dosimet-
ric accuracy for the tested criteria and detector methods.
Nelms et al. created four types of beam modeling errors,
including wrong MLC transmission factors and wrong beam
penumbra.48 The error-free plans were compared with error-
induced plans. Using c criteria of 3%/3 mm, 2%/2 mm, and
1%/1 mm criteria, they found only weak to moderate correla-
tions between conventional IMRT QA performance metrics
and clinically relevant dose-volume histograms differences.
Several recent studies demonstrated that common phantom-
based IMRT QA techniques are not highly sensitive to some
MLC leaf position errors67,124,126–128 or to clinically mean-
ingful errors67,.48,68–70,127,129
Kry et al. compared IROC Houston’s IMRT head and
neck phantoms results with those of in-house IMRT QA for
855 irradiations performed between 2003 and 2013.130 The
sensitivity and specificity of IMRT QA to detect unaccept-
able or acceptable plans were determined relative to the
IROC Houston phantom results. Depending on how the
IMRT QA results were interpreted, they showed IMRT QA
results from institutions were poor in predicting a failing
IROC Houston phantom result. The poor agreement between
IMRT QA and the IROC Houston phantoms highlighted the
inconsistency in the IMRT QA process across institutions.
McKenzie et al. investigated the performance of several
IMRT QA devices in terms of their ability to correctly iden-
tify dosimetrically acceptable and unacceptable IMRT pa-
tient plans, as determined by IROC-designed multiple ion
chamber phantom used as the gold standard.131 Using com-
mon clinical acceptance thresholds (c criteria of 2%/2 mm,
3%/3 mm, and 5%/3 mm), they found that most IMRT QA
devices performed very poorly in terms of identifying unac-
ceptable plans.
These studies highlighted the importance of adopting tigh-
ter tolerances, performing a thorough analysis, having pro-
grams for routine QA of the accelerator and MLC, as well as
developing new methods to supplement measurement-based
patient-specific QA.70,132 In addition, these studies high-
lighted the challenges of using c test passing rates for evaluat-
ing treatment plan acceptability and showed that clinical
analysis of IMRT QA failure results is a challenging task. As
discussed in Section 2.G.3., the c test could underestimate
the clinical consequences of certain dose delivery errors
when the c test is summarized in aggregate and when more
detailed examination of the c distribution is not conducted.
The c test passing rate summarization has no spatial sensitiv-
ity, similar to dose-volume histograms, and the location and
clustering of the failed points is not considered along with
the passing rate. Also, field-by-field evaluation and dosimet-
ric comparison might obfuscate clinically relevant dose errors
and make correlating test results with clinical acceptability
difficult. This is especially important because most compar-
isons are unable to reach 100% passing and so clinical criteria
allow a fraction of points to fail the c test. IMRT QA evalua-
tion of plans that have large regions of low dose cause the
fraction of failed points to appear small even when the area of
failed points is large compared to the high-dose regions, and
thus resulting in the c test passing easily.
5.C. Passing rates for given tolerances and
corresponding action limits
A number of groups have suggested metrics to assess the
clinical acceptability of IMRT QA verification plans.
Table III shows confidence limits (CL), action limits (AL),
tolerance limits (TL), and corresponding c thresholds
reported in the literature. Palta et al.35 proposed confidence
limits and action levels for a range of dose regions for IMRT
plan validation. The confidence limit was calculated as the
sum of the absolute value of the mean difference and the SD
of the differences multiplied by a factor of 1.96 (|mean devia-
tion|+1.96 SD). The mean difference used in the calculation
of confidence limit for all regions was expressed as a per-
centage of the prescribed dose according to the formula,
100% 9 (Dcalc  Dmeas)/Dprescribed. The confidence limit
formula was based on the statistics of a normal distribution
which expects that 95% of the measured points will fall
within the confidence limit. The confidence limit values were
derived from the results of an IMRT questionnaire from 30
institutions and reflected how the institutions judged the clin-
ical significance of tolerance limits used for IMRT QA. The
values were given as follows: (a) confidence limit of 10%
or 2 mm DTA and action level of 15% or 3 mm DTA for
the high dose, high gradient region, (b) confidence limit of
3% and action level of 5% for the high dose, low gradient
region, and (c) confidence limit of 4% and action level of
7% for the low dose, low gradient region. Palta et al.35 sug-
gested that IMRT treatment plans should not be used
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clinically if the measured and calculated doses differed by
more than the action level values.
Using the confidence limit formalism of Palta et al.,35
TG-119 reported confidence limits of 4.5% for a high-dose
point in the PTV and 4.7% for a low-dose point in an avoid-
ance structure, both measured using an IC. Confidence limits
of 12.4% and 7%, respectively, were reported for 2D
composite dose measurements made with film and arrays,
corresponding to 87.6% and 93% c passing rates (3%/
3 mm), respectively. Basran and Woo133 examined the dis-
crepancies between calculations and 2D diode array measure-
ments for 115 IMRT cases. They reported acceptable
tolerance limits of 3% overall, and 5% per-field, for absolute
dose differences (independent of disease site). They recom-
mended c thresholds ≥ 95% for non-HN cases and ≥ 88%
for HN cases using 3%/3 mm. The ESTRO38 report on
Guidelines for the Verification of IMRT reported the experi-
ence of a number of European centers. For IC verification
measurements, the report recommended a tolerance limit of
3% and an action limit of 5%.
Low and Dempsey43 in 2003 proposed the need for fairly
broad tolerances. They reported that for typical clinical use at
the time, the fraction of points that exceed 3% and 3 mm was
often extensive, so they used 5% and 2–3 mm as c tolerance
values for IMRT clinical evaluations. Childress et al.66 in
2005 analyzed 850 films resulting from IMRT plan verifica-
tion and reported a “preferred” c index tolerance criteria of
5% and 3 mm.
A number of groups suggested using a combination of the
mean c value, maximum c value exceeded by a given per-
centage of measurement points (e.g., 1%), and the fraction of
c values above one (P > 1) to analyze the c distributions and
make judgments on the agreement between measurements
and calculation based on clinically driven criteria.66,134–136
For example, Stock et al.134 used a c evaluation (3%/3 mm)
relative to maximum dose for nine IMRT plans to decide the
acceptability of IMRT verification QA. They considered a
plan to meet their pass criteria if the average c, maximum c,
and P > 1 were < 0.5, < 1.5, and 0–5%, respectively.
De Martin et al.137 analyzed the c histograms (4%/3 mm)
for 57 HN IMRT plans using c mean values, cD (where cD
was defined as cmean + 1.5 SD(c)), and the percentage of
points with c < 1, c < 1.5, and c > 2. They accepted the
IMRTverification QA depending on the confidence limit val-
ues. They reported cD < 1 and confidence limits of 95.3%,
98.9%, and 0.4% for the percentage of points with c < 1,
c < 1.5, and c > 2, respectively, for their newly installed
linac.
Bailey et al.103 compared measured dose planes with cal-
culations for 79 HN and 25 prostate IMRT fields. Passing
rates were calculated using dose difference/DTA, c evalua-
tion, and absolute dose comparison with both local and glo-
bal normalization. They reported the passing rate spread for
the individual prostate and HN fields with the greatest differ-
ences observed between global and local normalization meth-
ods. For 2%/2 mm and 3%/3 mm (10% dose threshold), the
TABLE III. IMRTverification QA confidence limits (CL), action limits (AL), tolerance limits (TL), and corresponding c thresholds reported in the literature.
Author year
Delivery
technique Dosimeter Number of irradiation Reported/recommended tolerance levels
Palta 200335 Fixed-gantry Not specified Results from an IMRT
questionnaire of 30
institutions
CL and AL: 10%/2 mm and 15%/3 mm (high dose, steep
gradient);
CL and AL: 3% and 5% (high dose, low gradient);
CL and AL: 4% and 7% (low dose, low gradient)
Low 200343 Fixed-gantry N/A Simulated fields
mimicking clinical
fields
c index tolerance criteria: 5%/2–3 mm
Childress 200566 Fixed-gantry Film 858 fields c index tolerance criteria: 5%/3 mm
Stock 2005134 Fixed-gantry Film, IC 10 plans c index (3%/3 mm): cmean < 0.5, cmax < 1.5, and fraction of
c>1 0–5%
De Martin 2007135 Fixed-gantry Film, IC 57 HN plans c index (4%/3 mm): cD [cmean + 1.5 SD(c)] < 1;
c threshold (4%/3 mm): c<1 > 95.3%, c<1.5 > 98.9%,
c>2 < 0.4%
ESTRO 200838 Fixed-gantry IC Not specified TL: 3%
AL: 5%
Basran 2008108 Fixed-gantry 2D diode array 115 plans TL: 3% overall, 5% per-field (independent of disease site);
c threshold (3%/3 mm): ≥95% (non-HN cases);
c threshold (3%/3 mm): ≥88% (HN cases)







CL: 4.5% (high-dose point in PTV);
CL: 4.7% (low-dose point in OAR);
CL: 12.4% (film composite), 87.6% passing (3%/3 mm);
CL: 7% (per-field), 93.0% passing (3%/3 mm)
Carlone 2013136 Fixed-gantry 2D diode array 85 prostate plans (68
modified with random
MLC errors)
c threshold (2%/2 mm): 78.9% (r~  3 mm), 84.6%
(r~  2 mm), 89.2% (r~  1 mm);
c threshold (3%/3 mm): 92.9% (r~  3 mm), 96.5%
(r~  2 mm), and 98.2% (r~  1 mm).
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prostate c passing rates were 80.4% and 96.7% for global
normalization and 66.3% and 90.8% for local normalization,
respectively. On the other hand, the HN passing rates were
77.9% and 93.5% for global normalization and 50.5% and
70.6% for local normalization, respectively.
Carlone et al.138 investigated the use of receiver operating
characteristic (ROC) methods in order to set tolerance limits
for c evaluations. They used a group of 17 prostate plans that
was delivered as planned and a second group of 17 prostate
plans that was modified by inducing random MLC position
errors. The errors were normally distributed with r  0.5,
1.0, 2.0, and 3.0 mm. A total of 68 modified plans were
created and evaluated using five different c criteria (5%/
5 mm, 4%/4 mm, 3%/3 mm, 2%/2 mm, 1%/1 mm). The
dose threshold used during the c evaluation process was not
reported. All plans were delivered on a 2D detector array sys-
tem with 7 mm detector spacing. Plots of the fraction of
fields with a passing rate greater than a user-defined thresh-
old ranging between 0% and 100% were plotted against pass
rate percentage. Plots were generated for each combination of
the five c criteria and four r. A total of 20 ROC curves were
then generated by varying the pass rate threshold and com-
puting for each point the fraction of failed modified plans,
and the fraction of passed unmodified plans. ROC evaluation
was performed by quantifying the fraction of modified plans
reported as “fail” and unmodified plans reported as “pass”.
Optimal tolerance limits were derived by determining which
criteria maximized sensitivity and specificity. Specifically, an
optimal threshold was identified by the point on the area
under the ROC curve closest to the point where sensitivity
and specificity equaled 1.
While the c criteria were able to achieve nearly 100% sen-
sitivity/specificity in the detection of large random MLC
errors (r > 3 mm), sensitivity and specificity decreased for
all c criteria as the size of error to be detected decreased
below 2 mm. The optimal passing threshold values for 2%/
2 mm were 78.9% (r = 3 mm), 84.6% (r = 2 mm), and
89.2% (r = 1 mm). The optimal passing threshold values for
3%/3mm were 92.9% (r = 3 mm), 96.5% (r = 2 mm), and
98.2% (r = 1 mm). Based on the ROC analysis, Carlone
et al. concluded that the predictive power of patient-specific
QA was limited by the size of error to be detected for the
IMRT QA equipment used in their center.
Bresciani et al.106 evaluated the variability of local and
global analysis for Tomotherapy plans using 3%/3 mm, 2%/
2 mm, and 1%/1 mm, each with both local and global nor-
malization. They reported mean passing rates for local (glo-
bal) normalization of 93% (98%) for 3%/3 mm, 84% (92%)
for 2%/2 mm, and 66% (61%) for 1%/1 mm. They investi-
gated the effect to excluding points below a 5% or 10% dose
threshold and found that the choice between these thresholds
did not affect the passing rate. They concluded that the vari-
ability in passing rates observed in their work showed the
need to establish new agreement criteria that could be univer-
sal and comparable between institutions.
Pulliam et al. performed 2D and 3D c analyses for 50
IMRT plans by comparing collapse-cone convolution TPS
(evaluated) and MC (reference) dose distributions.139 The
analysis was performed using a variety of dose differ-
ence (5%, 3%, 2%, and 1%) and DTA (5, 3, 2, and 1 mm)
acceptance criteria, low-dose thresholds (5%, 10%, and
15%), and grid sizes (1.0, 1.5, and 3.0 mm). A small differ-
ence between 2D and 3D c passing rates of 0.8% for 3%/
3 mm and 1.7% for 2%/2 mm was reported with no low-dose
threshold and a 1 mm grid size. 3D c analysis produced better
agreement than the corresponding 2D analysis. The addi-
tional degree of searching increased the percent of pixels
passing c by up to 2.9% in 3D analysis. The greatest differ-
ence between 2D and 3D c results was caused by increasing
the dose difference and DTA criteria.
6. VENDOR SURVEY AND ALGORITHM TESTING
In order to better understand the commercial implementa-
tion of IMRT QA c analysis software, TG-218 contacted the
vendors and provided them with a set of questions displayed
in Table IV and test cases. The tests examined vendor imple-
mentations of the c verification algorithm employing bench-
mark cases developed by TG-218.
TABLE IV. Vendor survey questionnaire on the implementation of IMRT QA
c analysis software.
1. Do you perform interpolation between points in the dose image__, if so, to
what resolution________?
2. Do you resample one or both images for the c analysis____? If so, on what
basis and to what
resolution_____________________________________________?
3. Which image is considered the reference image for the c analysis, plan or
measured__________? Is this user selectable?______
4. Can you use an acquired and plan dose image that are each in standard
DICOM RT format?______________________________
5. What search radius do you use, is it user selectable?____________
6. Do you offer both relative and absolute dose modes?__________
7. Is your dose tolerance part of the c analysis referred to the local dose or
maximum dose or other____? Is that user selectable_________?
8. Do you specify the dose threshold value above which the analysis will take
place? If so, what is the dose threshold?___ Is this value user
selectable_________?
9. Do you offer plan-to-acquired-dose image auto-registration___? Manual
registration___? Assume center of each image is point in
common__________?
10. For relative mode, how do you normalize the acquired and plan dose
images-
• at maximum?,
• to an area,
• to a user selectable point?
• Other ?_______________________________
11. Do you perform % dose difference-DTA(Van Dyk analysis)? __________
12. If so, how do you normalize the acquired and plan dose images-
• at maximum of the reference image?,
• an area,
• to a user selectable point?
• Other ? ________________________________
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6.A. Vendor survey
The vendor questionnaire in Table IV included questions
about the implementation of the c analysis tool for IMRT QA in
their software product. Eight vendors were contacted, and
responses were recorded: 3DVH and SNC Patient for Map-
CHECK and ArcCHECK (Sun Nuclear Corporation, Mel-
bourne, FL, USA), Portal Dosimetry with EPID (Varian
Medical Systems, Palo Alto, CA, USA), RIT 113 (Radiological
Imaging Technology, Inc, Colorado Springs, CO, USA),
IMSure (Standard Imaging Inc, Middleton, WI, USA), Delta4
(ScandiDos, Uppsala, Sweden), VeriSoft with Seven29 2D array
(PTW, Freiburg, Germany), COMPASS and OmniPro-IMRT
with MatriXX (IBA dosimetry, Schwarzenbruck, Germany).
The responses are summarized in Table V. Two items that stand
out in this table for improvement are that not every vendor is
providing interpolation between points for dose maps, and not
every vendor is providing dose difference/DTA analysis.
6.B. Testing of vendors algorithms
In addition to the difference in QA tool designs, such as
the detector type and electronics, the implementation of the
same IMRT QA analysis method, such as composite test and
c index, can vary from different vendors or even different
products from the same vendors. The differences could come
from the interpolation algorithm and resolution, DTA search
points and radius, normalization, etc., as indicated in the sur-
vey results in Table IV. These differences can lead to different
QA results.
There is no general specification for testing the dose anal-
ysis tools provided in the dosimetry software used for such
comparisons. Two tests were provided to the vendors for the
evaluation of their dose comparison software under well-
regulated conditions that span clinically relevant doses and
gradients, and to determine if they are producing the correct
result. Specifications for reference and evaluated dose





dosimetry RIT113 IMSure Delta 4 VeriSoft Compass
OP
IMRT
1. Perform interpolation between points: Yes Yes No No Yes Yes No Yes Yes
2. Resample one or both images for c analysis: No No Yes Yes Yes Yes Yes Yes Yes
3. Reference image is plan or measurement: Measured Plan Plan Both Plan Measured Measured Plan Both
User selectable No No No Yes No No No No Yes
4. Can user acquire and plan dose image in DICOMRT: Yes Yes Yes Yes No Yes Yes Yes Yes
5. DTA search radius (mm): 8 5 10 30 2.5xDTA 3
User selectable No No No Yes No No Yes No Yes
6. Offer both relative and absolute dose modes: Yes No Yes Yes No Yes Yes Yes Yes
7. Dose tolerance part of c user selectable: Yes Yes Yes Yes Yes Yes Yes Yes Yes
Local dose Yes Yes Yes Yes Yes Yes Yes Yes Yes
Max dose Yes Yes Yes Yes Yes Yes Yes Yes Yes
8. Dose threshold above c analysis occurs: 0–100% 0–100% 0–100% 0–100% 0–100% 0–30% 10cGy 0–100%
User selectable Yes Yes Yes Yes Yes Yes Yes Yes Yes
9. Registration between plan and measurement: Yes Yes Yes Yes No Yes Yes Yes Yes
Auto registration Yes Yes Yes Yes Yes Yes Yes No
Manual registration Yes No Yes Yes Yes Yes No Yes
Assume center of each image as common point Yes Yes No No No Yes No
10. Relative mode, normalize plan/measurement to: Yes No Yes Yes Yes Yes Yes Yes Yes
At maximum Yes No Yes Yes Yes Yes Yes Yes Yes
To an area No No No Yes Yes Yes Yes No Yes
User selectable point Yes No Yes Yes Yes Yes Yes Yes
Others Yes
11. Perform % dose difference/DTA(Van Dyk analysis): Yes Yes No Yes No Yes No Yes Yes
Normalize to maximum of reference image Yes Yes Yes Yes Yes
Normalize to an area No No Yes Yes Yes
Normalize to a user selectable point Yes No Yes Yes Yes Yes Yes
Others Yes
aVendors: 3DVH and SNC Patient for MapCHECK and ArcCHECK (Sun Nuclear Corporation, Melbourne, FL, USA), Portal Dosimetry with EPID (Varian Medical Sys-
tems, Palo Alto, CA, USA), RIT 113 (Radiological Imaging Technology, Inc, Colorado Springs, CO, USA), IMSure (Standard Imaging Inc, Middleton, WI, USA), Delta4
(ScandiDos, Uppsala, Sweden), VeriSoft with Seven29 2D array (PTW, Freiburg, Germany), COMPASS and OmniPro-IMRTwith MatriXX (IBA dosimetry, Schwarzen-
bruck, Germany).
bSurvey was conducted in 2014.
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distributions were given to test the basic functionality of their
dose comparison tools, including the dose difference and c
tools.
There were two types of distributions provided: (a) mathe-
matically defined distributions and (b) distributions based on
a clinical treatment plan. In both cases, the distributions were
2D with 0.5 mm resolution. The mathematically defined
dose distribution for a circular field contained three distinct
regions: first, a high and homogeneous dose area in the cen-
tral region set to 200 cGy with flat gradient; second, a linear
dose gradient (50% cm1) next to the central region, and
third a homogeneous low-dose region set to 8 cGy surround-
ing the high dose and linear gradient regions. The evaluated
dose distributions for the mathematically defined distribution
were the reference distributions perturbed by modifying
either the radiation dose gradient or the dose levels. Figure 7
shows examples of the reference and evaluated dose distribu-
tions. Also tested was a dose distribution acquired from a
clinical IMRT treatment plan and the measured 2D film dose
shown in Fig. 8.
The method by Ju et al.55 was used as the benchmark
(gold standard) for the commercial calculation evaluation.
The percentage of points passing dose difference and DTA
tolerances of all combinations of 2%, 3%, 2 mm, and 3 mm,
were utilized. For the mathematically defined plans, two low-
dose thresholds of 4% and 5.5% were also utilized. The dose
threshold to exclude low-dose areas in the clinical plans was
set to zero.
Five vendors responded with results. Table VI shows the
relative c passing rate for these vendors for the
(a) (b)
(c)
FIG. 7. Dose distributions for the mathematical case (circular-shape field) sent to vendors to test c calculations. (a) Reference dose distribution (resolution
0.5 mm). (b) Evaluated dose distribution (resolution 0.5 mm). (c) Overlaid dose profiles showing the differences between the two distributions.
(a) (b)
FIG. 8. Clinical dose distributions from a clinical IMRT plan sent to vendors to test c calculations. (a) TPS calculated dose distribution (resolution 0.5 mm). (b)
Film measurement (resolution 0.5 mm).
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mathematically defined plans. Table VII shows the relative
passing rates from clinical plan shown in Fig. 8. For the
mathematical and clinical tests, some vendors used the refer-
ence image as evaluated and the evaluated image as reference
due to their software design. As these data show, the passing
rates for the mathematically defined tests were calculated
within 0.1% for two vendors, and most other vendors were
within 6%. Vendor E had consistently greater passing rates
than the other vendors or the gold standard for the mathemat-
ical tests. The clinical plan showed more variation than the
mathematically defined tests. Comparing the film dose image
to the TPS dose, agreement with the gold standard was within
6% across all vendors.
These results indicate that the vendors are not using a stan-
dardized approach to implementing the dose comparison
tests. Given that the mathematically defined tests showed
excellent albeit not perfect agreement, the discrepancies in
the clinical case are likely due to the methods used to align
the doses or handling of image resolutions. This highlights
the fact that the user should understand how their vendor has
implemented the algorithm and should run benchmark test
cases against their algorithm to evaluate its accuracy.
7. PROCESS-BASED TOLERANCE AND ACTION
LIMITS
Although not explicitly mentioned in Section 1.C., there
is a human contribution to every IMRT QA measurement that
is a source of variation. Another source of variation is the
complexity of each IMRT case, for example, intensity modu-
lation differences between head and neck and prostate IMRT
cases. A process view of IMRT QA includes all sources of
variation mentioned in Section 1.C. as well as the human and
case-specific issues. Accounting for all aspects of variation in
IMRT QA can be achieved by setting process-based tolerance
and action limits.
Action limits should set a minimum level of process perfor-
mance such that IMRT QA measurements outside the action
limits could result in a negative clinical impact for the patient.
Tolerance limits refer to the range within which the IMRT QA
process is considered to be unchanging. An out-of-control pro-
cess serves as a warning that the process might be changing. If
an IMRT QA measurement is outside the tolerance limits but
within action limits, it is left up to the medical physicist to
determine whether or not action should be taken.
Action limits come in two categories: (a) those that are
universally defined and guided by outcomes data and expert
consensus, and (b) those that are locally defined and guided
by local experience. For any QA measurement, it is desirable
to use universal action limits as these should be directly cor-
related with treatment outcome. This implies that there is
some clinical evidence or a least consensus agreement among
experts perhaps guided by summary statistics of retrospective
data to inform the choice of those action limits. An example
of universally defined action limits are those for treatment
machine output because there is a direct correspondence









































3 3 4 95.1 95.1 0.0 95.3 0.2 95.1 0.0 95.1 0.0 96.4 1.4
3 2 4 90.2 90.2 0.0 89.8 0.4 90.2 0.0 90.2 0.0 91.4 1.3
2 3 4 93.4 93.4 0.0 93.7 0.3 93.4 0.0 93.4 0.0 94.7 1.4
2 2 4 88.3 88.3 0.0 88.2 0.1 88.3 0.0 88.3 0.0 89.6 1.5
3 3 5.5 81.9 81.9 0.0 81.6 0.4 80.4 1.8 81.9 0.0 85.8 4.8
3 2 5.5 63.1 63.1 0.0 59.8 5.2 61.0 3.3 63.1 0.1 65.8 4.3
2 3 5.5 75.3 75.3 0.0 75.1 0.3 73.9 1.9 75.2 0.1 79.0 4.9
2 2 5.5 55.4 55.4 0.0 53.6 3.3 53.4 3.6 55.4 0.1 58.5 5.6











































3 3 0 98.7 98.5 0.2 96.7 2.0 98.5 0.2 98.5 0.2 97.0 1.7
3 2 0 97.1 96.5 0.6 94.5 2.7 96.5 0.6 96.5 0.6 95.4 1.8
2 3 0 96.6 96.1 0.5 91.6 5.2 96.1 0.5 96.1 0.5 92.3 4.5
2 2 0 93.0 92.1 1.0 87.2 6.2 92.1 1.0 92.1 1.0 88.7 4.6
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between treatment outcome and output. Exceeding action
limits that are locally defined do not necessarily result in
harm to a patient when exceeded, but in the interest of good
patient care, it is deemed best to keep process performance
within those limits. Patient-specific IMRT QA is an example
of action limits being set in this fashion. Locally defined
action limits may vary from institution to institution or case-
type to case-type since those limits are based on local equip-
ment, processes, and case types as well as the experience of
the local physicist.
Using methods from statistical process control,140–142
IMRT QA measurements can be used to determine action
limits when universal action limits are not appropriate.
Action limits determined in this fashion can be procedure-,
equipment-, and site-specific for each individual institution
and are calculated using the following equation,45
DA ¼ b
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
r2 þ x Tð Þ2
q
(3)
where DA is the difference between the upper and lower
action limits, typically written as A=2. T is the process tar-
get value and r2 and x are the process variance and process
mean, respectively. The constant b is a combination of two
factors. One factor originates from the process capability
metric, Cpm, as a cutoff for an acceptably performing pro-
cess143 and is combined with another factor that balances
type I errors (rejecting the null hypothesis when it is true)
and type II errors (not rejecting the null hypothesis when it is
false) when using an IMRT QA measurement to make a deci-
sion about process performance. In using IMRT QA mea-
surements to make decisions about process performance, the
null hypothesis is that the process is unchanging. Current
information suggests that b = 6.0 is an appropriate value to
use45 although this may be refined upon further research.
Using Eq. (3) will likely result in action limits than are wider
than what is currently accepted but should allow medical
physicists to focus on problems with patient-specific IMRT
QA that are likely to have identifiable causes. If the target, T ,
is known as in the example of patient-specific IMRT QA
point-dose difference (i.e., 0%) or c passing rate (i.e., 100%),
then the known target value should be used. If the target value
is unknown or not defined, then the process average can be
used as a best estimate of the target. This latter approach will
have the effect of tightening the action limits compared to the
former approach.
In this procedure, the process average, x, and variance, r2,
are calculated from the IMRT QA measurements over a time
period when the process does not display out-of-control
behavior. If the process is out-of-control, then one must iden-
tify and remove the reason for the out-of-control process
behavior and continue monitoring the process until it displays
a degree of control for about an additional 20 IMRT QA mea-
surements. Then, control chart limits from an I-chart of indi-
vidual IMRT QA measurements are used as the tolerance
limits. The I-chart is a statistical tool that helps identify any
IMRT QA measurement that displays abnormal (out-of-con-
trol) process behavior. The I-chart has upper and lower limit
lines (called control limits) and a center line that are calcu-
lated using the IMRT QA measurements.140–142 Out-of-con-
trol process behavior is indicated when any one IMRT QA
measurement is outside the upper or lower control limits on
the I-chart. The IMRT QA measurements should be some-
what equally distributed above and below the center line. The
center line, upper control limit, and lower control limits for
an I-chart are calculated using the following equations:





upper control limit ¼ center lineþ 2:660  mR (5)
lower control limit ¼ center line 2:660  mR (6)
where x is an individual IMRT QA measurement, n is the
total number of measurements, and mR ¼ 1n1
Pn
i¼2
jxi  xi1j is
the moving range.
In this procedure, the control limits are used at the toler-
ance limits. Establishing process control is a key element of
this procedure because a controlled process is an indication
that the process is stable and suitable for the purpose of
IMRT QA. Using the proposed procedure requires a different
view of QA such that measurements provide a description of
the entire process (people + equipment + procedures) and not
just the hardware and software equipment by itself. It is
important to note tolerance limits will depend on plan com-
plexity due to a greater case-to-case measurement variability.
Therefore, it can be good practice to calculate tolerance limits
separately for cases with high plan complexity and those with
lower plan complexity, for example, for head and neck IMRT
QA compared to prostate IMRT QA.
Two examples of process-based tolerance and action limits
are provided here to illustrate the procedure described in this
section. The processes are VMAT and fixed-gantry IMRT
QA and the c passing rates with 3%/2 mm and a 10% dose
threshold are used as the QA measure using an ArcCHECK
and MapCHECK device, respectively. Considering the
VMAT QA example with 20 c passing rates with an average
of 96.66%, standard deviation of 1.739%, and moving range
of 1.905%, then the action limit range following Eq. (3) is
22.6% which translates to an action limit of 100–22.6%/
2 = 88.7% (note that c is bounded at 100% for the upper
limit). As long as the process is not out-of-control, the control
chart limit will be used as the tolerance limits calculated
using Eq. (6) which is 96.66%–2.6601.905% = 91.6% for
this example. For the fixed-gantry IMRT QA example, the 20
c passing rates with an average of 95.92%, standard deviation
of 3.388%, and moving range of 3.642%, then the action
limit is 84.1% and the tolerance limit is 86.2%. In the case of
c passing rates, the upper tolerance (control) limit and action
limit are bounded and equal to 100%.
The last step in the procedure is to compare the tolerance
limits to the action limits. For example if the c tolerance lim-
its are lower than the action limits, then either the process
needs to be fixed or the action limits lowered (i.e., use a
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larger value of b in Eq. (3)). Fixing the process may require
new or modified equipment or training of personnel perform-
ing the IMRT QA measurements and analysis. Using this
standardized procedure for setting action and tolerance limits
will allow medical physicists to compare IMRT QA processes
across institutions. The full procedure is summarized in
Fig. 9.
8. RECOMMENDATIONS
8.A. IMRT QA, tolerance limits, and action limits
Published data on IMRT QA results and the clinical
experience of the group members were used to develop
guidelines and provide recommendations on universal toler-
ance and action limits for IMRT verification QA using the
c method. This included in-depth literature review of IMRT
QA results, analysis of widely used IMRT QA delivery and
evaluation methods, and operational details that can
improve the effectiveness and accuracy of the c method.
End-to-End QA verification tests for the IMRT TPS and
IMRT delivery equipment, along with patient-specific veri-
fication QA are required to evaluate the accuracy of radia-
tion delivery to patients. Tolerances, action limits, and
pass/fail criteria should be defined to evaluate the accept-
ability of IMRT QA verification plans.
We recommend the following terminology as it pertains to
IMRT QA delivery methods (see Section 3).
• Perpendicular field-by-field (PFF): the radiation beam
is perpendicular to the plane of the measurement
device. The device can be placed on the couch or
attached to the gantry head. The dose from each of the
IMRT beams is delivered and analyzed.
FIG. 9. Flow chart outlines the procedure for setting tolerance and action limits for IMRT QA.
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• Perpendicular composite (PC): the radiation beam is
always perpendicular to the measurement device detec-
tor plane. The device can be placed on the couch or
attached to the gantry head. The doses from all IMRT
radiation beams are delivered and subsequently
summed.
• True Composite (TC): all of the radiation beams are
delivered to a stationary measurement device in a phan-
tom placed on the couch using the actual treatment
beam geometry for the patient, including MUs, gantry,
collimator, couch angles, jaws, and MLC leaf positions.
This method most closely simulates the treatment deliv-
ery to the patient.
We make the following recommendations for IMRT QA
verification of dose distributions (fixed-gantry IMRT and
rotational IMRT):
• IMRT QA measurements should be performed using
the TC delivery method provided that the QA device
has negligible angular dependence or the angular
dependence is accurately accounted for in the vendor
software.
• IMRT QA measurements should be performed using
the PFF delivery method if the QA device is not suit-
able for TC measurements, or for TC verification error
analysis.
• IMRT QA measurements should not be performed
using the PC delivery method which is prone to mask-
ing delivery errors.
• Analysis of IMRT QA measurements and the corre-
sponding treatment plan should be performed in abso-
lute dose mode, not relative dose (the user should not
normalize the dose to a point or region, ie., relative dose
mode).
• A dose calibration measurement compared against a
standard dose should be performed before each mea-
surement session to factor the variation of the detector
response and accelerator output into the IMRT QA
measurement.
• Global normalization should be used. Global normal-
ization is deemed more clinically relevant than local
normalization. The global normalization point should
be selected whenever possible in a low gradient region
with a value that is ≥ 90% of the maximum dose in the
plane of measurement. This will provide a more realis-
tic measure of the comparison between the two dose
distributions.
• Local normalization is more stringent than global nor-
malization for routine IMRT QA. It can be used during
the IMRT commissioning process and for troubleshoot-
ing IMRT QA.
• The dose threshold should be set to exclude low-dose
areas that have no or little clinical relevance but can
significantly bias the analysis. An example is setting
the threshold to 10% in a case where the critical
structure dose tolerance exceeds 10% of the prescrip-
tion dose. This allows the c passing rate analysis to
ignore the large area or volume of dose points that lie
in very low-dose regions which, if included, would
tend to increase the passing rate when global normal-
ization is used.
Tolerance and action limits (terms were defined in Sec-
tion 1.C.) are the foundation for a robust IMRT QA verifica-
tion process. We make the following recommendations
regarding tolerance limits and action limits for evaluating the
IMRT QA analysis, including measurements. The limits are
the same for PFF and TC delivery methods, and assume the
tolerance and action limits are coincident with the goals of
the treatment plan. If they are not, for example stereotactic
radiosurgery (SRS) and stereotactic body radiotherapy
(SBRT) cases, tighter tolerances should be considered. The
following recommendations are for c analysis using global
normalization in absolute dose:
• Universal tolerance limits: the c passing rate should be
≥ 95%, with 3%/2 mm and a 10% dose threshold.
• Universal action limits: the c passing rate should be
≥ 90%, with 3%/2 mm and a 10% dose threshold.
○ If the plan fails this action limit, evaluate the c failure
distribution and determine if the failed points lie in
regions where the dose differences are clinically irrel-
evant, in which case the plan may be clinically
acceptable. If the c failure points are distributed
throughout the target or critical structures and are at
dose levels that are clinically relevant, the plan
should not be used and the medical physicist should
follow the steps outlined in section (b) below. It may
be necessary to review results with a different detec-
tor or different measurement geometry. For example,
if the failure is seen with the TC delivery, a PFF anal-
ysis can be valuable to further explore the discrepan-
cies between calculations and measurements.
• Equipment- and site-specific limits can be set following
the method described in Section 7.
○ If action limits are determined that are significantly
lower than the universal action limits recommended
above, then action should be taken as outlined in sec-
tion (b) below to improve the IMRT QA process.
From a process perspective, strict adherence to stan-
dardized procedures and equipment as well as addi-
tional training may also be necessary.
• Tighter criteria should be used, such as 2%/1 mm or
1%/1 mm to detect subtle regional errors and to discern
if the errors are systematic for a specific treatment site
or delivery machine.
• For IMRT QA performed with an IC and film, tolerance
and action limits for the ion chamber measurement
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should be within ≤ 2% and ≤ 3%, respectively, and the
film c passing rate limits should be assessed as speci-
fied above. An IMRT treatment plan should not be used
if the chamber measurement error or the c passing rate
exceeds the universal action limits.
• For any case with c passing rate less than 100%,
○ the c distribution should be carefully reviewed rather
than relying only on distilled statistical evaluations,
○ review of c results should not be limited to only the
percentage of points that fail, but should include
other relevant c values (maximum, mean, minimum,
median), as well as a histogram analysis.
○ An analysis of the maximum c value and the per-
centage of points that exceed a c value of 1.5
should be performed. For a 3%/2 mm, a c value of
1.5 could indicate a dose difference of 4.5% in a
low-dose gradient region or a DTA of ~3.0 mm in
a steep dose gradient region. Both of these are
examples of failures, but failures that exceed toler-
ances by 1.5% and 1 mm in the low and steep dose
gradient regions, respectively. Such information
should be used to deduce clinical relevance when-
ever possible (e.g., cluster of failing points near or
at the boundary of a tumor and critical structure).
• The IMRT treatment process should be monitored
and thoroughly investigated if the c passing rate is
systematically lower than the tolerance limits or
higher than the action limits. This includes reviewing
dose differences directly without c criteria or using
local dose normalization and tighter dose difference
and DTA criteria.
• c statistics should be reviewed on a structure by struc-
ture basis if the user software allows for it. Vendors
should include this feature in their future software
development.
• Track c passing rates across patients, especially for the
same tumor sites, to look for systematic errors in the
system.
• Vendors should implement a c tracking feature across
patients and for the same tumor sites in their future soft-
ware development.
• Vendors should implement the simplex method for
interpolation-free c calculation and make the c tool
more practical and accurate.55
• Whenever referring to a c passing rate, always specify
the dose difference (global or local) and DTA criteria
and the dose threshold. Without these parameters, the
passing rate is meaningless.
• Software tools that can provide a measure of the agree-
ment between measured and calculated DVHs of patient
structures are preferred over analysis in phantoms. DVH
analysis can be used to evaluate the clinical relevance of
the QA results, especially when the c passing rate fails
the tolerance limits or is inconsistent.
The accuracy of IMRT delivery can be affected by dif-
ferences and limitations in the design of the MLC and
accelerators among the different manufacturers, including
the treatment head design, as well as the age of the acceler-
ator/equipment. In addition, IMRT dosimetry QA equip-
ment design, tumor sites (e.g., HN vs. prostate), complexity
of the IMRT plans, uncertainties, inaccuracies and toler-
ances in the planning, delivery, and measurement may
affect the IMRT QA verification results. For centers with
IMRT QA results that are unable to meet the tolerance and
action limit values recommended in this report, the centers
should perform a comprehensive analysis to determine the
sources for these differences and remedy them. For exam-
ple, the use of statistical process control methods can be
useful in identifying the outlier cases failing to pass the tol-
erance limits for in-depth analysis.44,45 Also, it can be help-
ful to perform the TG-119 recommended tests and then
compare to the published results or conduct independent
tests using the IROC Houston IMRT phantoms. The recom-
mendations and guidelines provided in this report can be
applied for any modulated treatment fields regardless of the
system used to generate them. Finally, future research
efforts should be focused on further improving the correla-
tion between IMRT QA evaluation metrics and underlying
planning or delivery errors.
8.B. Course of actions to check and evaluate failed
or marginal IMRT QA results
IMRT QA verification results may not pass the tolerance
limits and/or action limits provided in this report. When
encountering a failure, the medical physicist should investi-
gate the potential reasons for the IMRT QA failure following
these recommendations.
The following, and/or the items considered necessary,
should be checked with respect to each system in the order
given:
8.B.1. Setup and Beam
• Phantom setup
• Correct plan version received by, and/or approved in,
the record and verify (R&V) system
• Correct QA plan generated, correct dose per fraction,
correct delivery technique and data transferred from
TPS to IMRT QAverification software
• Beam flatness, symmetry, and output on the day of the
measurement
• Beam stability when delivering many segments with
low MUs144
• Accuracy, stability, and calibration of the measurement
device
• Detector size and interdetector spacing with respect to
the size of the IMRT fields, especially for SRS and
SBRT cases
• Dose value of the global normalization point
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8.B.2. IMRT QA software
• Correct reporting and handling of the plan and mea-
sured data
• Recheck values used for dose and DTA tolerance, dose
threshold, and registration of the measured and calcu-
lated dose distributions
8.B.3. Multileaf Collimator (MLC)
• Review results of periodic general patient-specific
IMRT QA
• Leaf tolerances (speed, position, acceleration/decelera-
tion)
• Tongue-and-groove effects which may require a mea-
surement with a high-resolution detector
• Beam profile data for both collimator- and MLC-
defined fields
• Dynamic leaf-gap for rounded-leaf ends
• Intra- and interleaf transmission
• Jaw tracking positions (to minimize leaf transmission)
8.B.4. Treatment planning system (TPS)
• The amount of modulation and the complexity of inten-
sity patterns in the plan
• The total number of small segments in the plan, includ-
ing small elongated fields
• The total number of monitor units which affects the
total transmission dose and is related to plan complex-
ity
• TPS modeling accuracy for small-fields, including out-
put factors, profiles, and penumbra
• Characterization of the leaf-parameters in the TPS,
including MLC transmission, gap and rounded-leaf
ends
• Minimum MU numbers
• The minimum segment (or beamlet) size in the TPS
• The dose calculation grid size in the TPS for non-
Monte Carlo (MC) algorithms and the variance setting
for MC algorithms
• The IMRT QA device CT numbers to electron density
conversion
• Use of multiple carriage beams
• Gantry-angle spacing for VMAT delivery
• The above treatment planning items should be thor-
oughly checked as part of the IMRT TPS commissioning
process. The commissioning should also include verifi-
cation of IMRT plans for a full range of clinical cases,
dose calculation algorithm and optimization parameters.
If the IMRT verification plan fails and there is more com-
plex modulation than normal in your clinical practice, the
planner should consider replanning the IMRT case and
attempt to achieve the planning objectives with less complex
intensity patterns. In most systems, the planner can use tools
to smooth the patterns during delivery without compromising
plan quality.
9. CONCLUSIONS
IMRT is becoming the standard of care for many disease
sites. Recommendations were proposed in this report to ensure
the appropriate implementation of patient-specific IMRT QA
and the appropriate use of QA tools and methodologies. The
report provides in-depth analysis on QA tools and practical
recommendations on the use of the c metric for IMRTverifica-
tion. Vendor differences in c analysis were presented. It
demonstrated the need for the vendors to improve the imple-
mentation of the c tool and remove this additional source of
uncertainty from the IMRT QA process. Action limits using c
passing criteria were recommended to define the degree to
which the quality measures are allowed to vary without risking
harm to the patient and when clinical action is required. Toler-
ance limits using c passing criteria were recommended to
define the normal operating boundary of the IMRT QA verifi-
cation process. The recommendations presented in the report
provide suggested standards that can be implemented at the
clinical level to evaluate the acceptability of patient-specific
IMRT QA plans. They are intended to aid in the establishment
of universal and comparable criteria among institutions.
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